<SEC-DOCUMENT>0001140361-22-008622.txt : 20220309
<SEC-HEADER>0001140361-22-008622.hdr.sgml : 20220309
<ACCEPTANCE-DATETIME>20220309162121
ACCESSION NUMBER:		0001140361-22-008622
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20220306
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220309
DATE AS OF CHANGE:		20220309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Brooklyn ImmunoTherapeutics, Inc.
		CENTRAL INDEX KEY:			0000748592
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				311103425
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11460
		FILM NUMBER:		22725630

	BUSINESS ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220
		BUSINESS PHONE:		(212) 582-1199

	MAIL ADDRESS:	
		STREET 1:		140 58TH STREET, BUILDING A
		STREET 2:		SUITE 2100
		CITY:			BROOKLYN
		STATE:			NY
		ZIP:			11220

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN BUZZTIME INC
		DATE OF NAME CHANGE:	20051230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTN COMMUNICATIONS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALROY INDUSTRIES INC
		DATE OF NAME CHANGE:	19850411
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>brhc10034972_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:btx="http://brooklynitx.com/20220306" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_6ca1d790ca5448a595c0e90a908da3ea" contextRef="c20220306to20220306" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_80970cb4eb9a479f8a3e1058b8bb3d45" contextRef="c20220306to20220306">0000748592</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="btx-20220306.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20220306to20220306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000748592</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-06</xbrli:startDate><xbrli:endDate>2022-03-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
    <div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="z_Hlk93049658"></a><span style="font-size: 14pt;">UNITED STATES</span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_de9b323e470c4d9ba6a5cd4240e0eb56" contextRef="c20220306to20220306">8-K</ix:nonNumeric></div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_ceec8bd6e60845cf87a5fecdeb4f69d8" contextRef="c20220306to20220306" format="ixt:datemonthdayyearen">March 6, 2022</ix:nonNumeric></div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_dae207efe8374c9a813483d7b1325129" contextRef="c20220306to20220306">Brooklyn ImmunoTherapeutics, Inc.</ix:nonNumeric><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Exact Name of Registrant as Specified in its Charter)</div>

      <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman';"> <br />
        </span></div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.61%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_2a716859b9ba47409222e1ebdb391a9b" contextRef="c20220306to20220306" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33.68%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_2c7595ddd244428797f4c17844692594" contextRef="c20220306to20220306">001-11460</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 33%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_c4ec5567f855490b9f8ca55115368560" contextRef="c20220306to20220306">31-1103425</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 32.61%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(State or Other Jurisdiction of Incorporation)</div>
            </td>

    <td style="width: 33.68%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Commission File Number)</div>
            </td>

    <td style="width: 33%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(IRS Employer Identification No.)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_871da459a47046d78969461a08dbff8f" contextRef="c20220306to20220306">140 58th Street, Building A</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" id="Fact_95d39381160440fa9a231b2d495ba5f8" contextRef="c20220306to20220306">Suite 2100</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_7735424b6d844ac4bbd414f70d15e5d7" contextRef="c20220306to20220306">Brooklyn</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_3edc5df86a254dac8f6879143da2dc39" contextRef="c20220306to20220306" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric></div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_27b97b81eaa949509e4877eaf7f3655c" contextRef="c20220306to20220306">11220</ix:nonNumeric><br />
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.01%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Address of Principal Executive Offices)</div>
            </td>

    <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-style: italic;">(Zip Code)</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-weight: bold;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_7376f54987ad4649b1d18e8385c14f4b" contextRef="c20220306to20220306">212</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_c65f65a7b8544417b721685870492201" contextRef="c20220306to20220306">582-1199</ix:nonNumeric></span></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
        provisions:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_8edcaa177fea4e48a056519d518f7b24" contextRef="c20220306to20220306" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_f83c1bddc44640738ab8224f169965db" contextRef="c20220306to20220306" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_5b24e5a854134768a158b073539ceef0" contextRef="c20220306to20220306" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_d20291bcf2b0451d89fa143ee1c331d2" contextRef="c20220306to20220306" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Title of each class</div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Trading symbol</div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center; font-weight: bold;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_ed3423f0a8b44415b9c226aed323ad93" contextRef="c20220306to20220306">Common Stock, par value $0.005 per share</ix:nonNumeric><br />
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_8f4119001c4a483abd61dd38535bae00" contextRef="c20220306to20220306">BTX</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 2%; vertical-align: middle; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 32%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: center;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_e2b5d0117fe34d7f8fd07ceab627d657" contextRef="c20220306to20220306" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities
        Exchange Act of 1934:</div>

      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_2342a3cbf2034ff7a60e5181d9083891" contextRef="c20220306to20220306" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
        financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 1.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
                <div style="color: rgb(0, 0, 0); font-weight: bold;">Entry into a Material Definitive Agreement.</div>
              </td>

  </tr>


</table>
        <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 6, 2022, Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into a Securities Purchase Agreement (the
        &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;Purchaser&#8221;) providing for the private placement (the &#8220;Private Placement&#8221;) to the Purchaser of 6,857,142 units (collectively, the &#8220;Units&#8221;), each Unit consisting of (i) one share of the Company&#8217;s common
        stock, par value $0.005 per share (&#8220;Common Stock&#8221;) (or, in lieu thereof, one pre-funded warrant to purchase one share of Common Stock (the &#8220;Pre-Funded Warrants&#8221;)) and (ii) one warrant to purchase one share of Common Stock (the &#8220;Common Warrants&#8221;
        and, together with the Pre-Funded Warrants, the &#8220;Warrants&#8221;), for an aggregate purchase price of approximately $12.0 million (or $1.75 per share of Common Stock or $1.75 less $0.005 per Pre-Funded Warrant). The closing of the Private Placement
        occurred on March 9, 2022 (the &#8220;Closing&#8221;).</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Each Pre-Funded Warrant has an exercise price of $0.005 per share of Common Stock, is immediately exercisable and may be exercised at any time and
        has no expiration date, and is subject to customary adjustments. The Pre-Funded Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof would exceed 9.99% immediately after exercise
        thereof.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Each Common Warrant has an exercise price of $1.91 per share, becomes exercisable six months following the Closing, and expires five-and-one-half
        years from the date of issuance, and is subject to customary adjustments. The Common Warrants may not be exercised if the aggregate number of shares of the Company&#8217;s common stock beneficially owned by the holder thereof would exceed 4.99%
        immediately after exercise thereof, subject to increase to 9.99% at the option of the holder.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company intends to use the net proceeds from the Private Placement for general working capital purposes.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The securities issued to the Purchaser under the Purchase Agreement were offered in reliance on an exemption from registration provided by Section
        4(a)(2) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Rule 506 of Regulation D promulgated thereunder. The Company relied on this exemption from registration based in part on representations made by the Purchaser, including
        that the Purchaser is an &#8220;accredited investor&#8221;, as defined in Rule 501(a) promulgated under the Securities Act.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Cantor Fitzgerald &amp; Co. served as the placement agent in connection with the Private Placement, and the Company has agreed to pay customary
        placement fees of the placement agent.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The sale of the securities pursuant to the Purchase Agreement has not been registered under the Securities Act or any state securities laws. The
        securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Neither this Current Report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the
        solicitation of an offer to buy the securities described herein or therein.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company and the Purchaser also entered into a Registration Rights Agreement, dated March 6, 2022, pursuant to which the Company has agreed to
        prepare and file a registration statement with the Securities and Exchange Commission no later than 15 days following the date on which the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, to register the
        resale of the shares of Common Stock included in the Units and the shares of Common Stock issuable upon exercise of the Warrants. The Company agreed to use its best efforts to have such registration statement declared effective as promptly as
        possible after the filing thereof, subject to certain specified penalties if timely effectiveness is not achieved.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The foregoing description of the Purchase Agreement, the Pre-Funded Warrants, the Common Warrants and the Registration Rights Agreement is only a
        summary and is qualified in its entirety by reference to the full text of such agreements, which are filed as Exhibits 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 3.02</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Unregistered Sales of Equity Securities.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The information contained in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference in response to this Item 3.02.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 8.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Other Events.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">On March 7, 2022, the Company issued a press release in accordance with Rule 135c promulgated under the Securities Act announcing the Private
        Placement.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In accordance with Rule 135c(d), a copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by
        reference in this Item 8.01.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d) Exhibits.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exhibit</div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div>
              </div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="text-align: center; font-weight: bold;">Description</div>
              </div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><a href="brhc10034972_ex10-1.htm">10.1</a></div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Securities Purchase Agreement, dated as of March 6, 2022, between Brooklyn ImmunoTherapeutics, Inc. and the purchaser party thereto.</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><a href="brhc10034972_ex10-2.htm">10.2</a></div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Form of Pre-Funded Warrant</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><a href="brhc10034972_ex10-3.htm">10.3</a></div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Form of Common Stock Warrant</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><a href="brhc10034972_ex10-4.htm">10.4</a></div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Registration Rights Agreement, dated as of March 6, 2022, between Brooklyn ImmunoTherapeutics, Inc. and the purchaser party thereto.</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;"><a href="brhc10034972_ex99-1.htm">99.1</a></div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Press Release dated March 7, 2022.</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td rowspan="1" style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: center;">104</div>
            </td>

    <td colspan="1" style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 87.64%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(204, 238, 255);">
              <div style="text-align: justify;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="DSPFPageBreakArea">
        <div style="page-break-after:always;" class="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      </div>

      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
        duly authorized.</div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td colspan="3" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left; font-variant: small-caps;">Brooklyn ImmunoTherapeutics, Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td colspan="3" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Dated: March 9, 2022</div>
            </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">By:</div>
            </td>

    <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">/s/ <span style="font-variant: small-caps;">Howard J. Federoff</span></div>
            </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Howard J. Federoff</div>
            </td>

    <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.72%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br />
            </td>

    <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="text-align: left;">Chief Executive Officer and President</div>
            </td>

  </tr>


</table>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br />
      </div>

    </div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /> </div>

  </div>

  <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>brhc10034972_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%%%-->
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="text-align: right; font-weight: bold;">Exhibit 10.1<br>
  </div>
  <div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SECURITIES PURCHASE AGREEMENT</div>
    <div>&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">This Securities Purchase Agreement (this &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;) is dated as of
      March 6, 2022, between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), and each purchaser identified on the signature pages hereto (each,
      including its successors and permitted assigns, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchaser</u></font>&#8221; and collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchasers</u></font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and
      Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and
      adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE I.</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">DEFINITIONS</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">1.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Definitions</u></font>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section
        1.1:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Acquiring Person</u></font>&#8221; shall have the
      meaning ascribed to such term in Section 4.5.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Action</u></font>&#8221; shall have the meaning ascribed to such term
      in Section 3.1(j).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Affiliate</u></font>&#8221; means any Person that, directly or
      indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Board of Directors</u></font>&#8221; means the board of directors of
      the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Business Day</u></font>&#8221; means any day other than Saturday,
      Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed;<font style="font-size: 10pt; font-family: 'Times New Roman';">&#160;<u>provided</u>, <u>however</u>, for clarification, commercial
        banks shall not be deemed to be authorized or required by law to remain closed due to &#8220;stay at home&#8221;, &#8220;shelter-in-place&#8221;, &#8220;non-essential employee&#8221;&#160; or any other similar orders or restrictions or the closure of any physical branch locations at the
        direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are open for use by customers on such day</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Closing</u></font>&#8221; means the closing of the purchase and sale
      of the Securities pursuant to Section 2.1.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">1</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Closing Date</u></font>&#8221; means the Trading Day on which all of
      the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers&#8217; obligations to pay the Subscription Amount and (ii) the Company&#8217;s obligations to deliver the Securities,
      in each case, have been satisfied or waived.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Commission</u></font>&#8221; means the United States Securities and
      Exchange Commission.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Common Stock</u></font>&#8221; means the common stock of the Company,
      par value $0.005 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Common Stock Equivalents</u></font>&#8221; means any securities of the
      Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or
      exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Common Warrant Shares</u></font>&#8221; means the shares of Common
      Stock issuable upon exercise of the Common Warrants.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Common Warrants</u></font>&#8221; means, collectively, the Common
      Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be exercisable on the date that is six months following the Closing Date and have a term of exercise equal to five (5)
      years and six (6) months, in the form of <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit A</u></font> attached hereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company Counsel</u></font>&#8221; means Greenberg Traurig, P.A., with
      offices located at 333 S.E. 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Avenue, Suite 4400, Miami, Florida 33131.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Disclosure Schedules</u></font>&#8221; means the Disclosure Schedules
      of the Company delivered concurrently herewith.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Disclosure Time</u></font>&#8221; means, (i) if this Agreement is
      signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date hereof, unless otherwise
      instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
      hereof, unless otherwise instructed as to an earlier time by the Placement Agent.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Effective Date</u></font>&#8221; means the earliest of the date that
      (a) <a name="z_Hlk86323323"></a>the initial Registration Statement registering for resale all Shares and Warrant Shares has been declared effective by the Commission, (b) all of the Shares and Warrant Shares have been sold pursuant to Rule 144 or
      may be sold pursuant to Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions, (c) following the one year anniversary of the
      Closing Date provided that a holder of Shares or Warrant Shares is not an Affiliate of the Company, or (d) all of the Shares and Warrant Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act without
      volume or manner-of-sale restrictions and Company Counsel has delivered to such holders a copy of a customary written legal opinion issued to the Company&#8217;s transfer agent that resales may then be made by such holders of the Shares and Warrant Shares
      pursuant to such exemption which opinion shall be in form and substance reasonably acceptable to such holders. &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Evaluation Date</u></font>&#8221; shall have the meaning ascribed to such term
      in Section 3.1(s).</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exchange Act</u></font>&#8221; means the Securities Exchange Act of
      1934, as amended, and the rules and regulations promulgated thereunder.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exempt Issuance</u></font>&#8221; means the issuance of (a) shares of
      Common Stock or options to employees, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a
      committee of non-employee directors established for such purpose for services rendered to the Company, (b) warrants to the Placement Agent in connection with the transactions pursuant to this Agreement and any securities upon exercise of warrants to
      the Placement Agent, securities upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of
      this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in
      connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that
      such securities are issued as &#8220;restricted securities&#8221; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.11(a)
      herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the
      Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose
      primary business is investing in securities.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>FCPA</u></font>&#8221; means the Foreign Corrupt Practices Act of
      1977, as amended.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>GAAP</u></font>&#8221; shall have the meaning ascribed to such term in
      Section 3.1(h).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indebtedness</u></font>&#8221; shall have the meaning ascribed to such
      term in Section 3.1(bb).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Intellectual Property Rights</u></font>&#8221; shall have the meaning
      ascribed to such term in Section 3.1(p).</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Legend Removal Date</u></font>&#8221; shall have the meaning ascribed
      to such term in Section 4.1(c).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Liens</u></font>&#8221; means a lien, charge pledge, security
      interest, encumbrance, right of first refusal, preemptive right or other restriction.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Lock-Up Agreement</u></font>&#8221; means the Lock-Up Agreement, dated
      as of the date hereof, by and among the Company and the Company&#8217;s directors and officers, in the form <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit B</u></font> attached hereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Material Adverse Effect</u></font>&#8221; shall have the meaning
      assigned to such term in Section 3.1(b).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Material Permits</u></font>&#8221; shall have the meaning ascribed to
      such term in Section 3.1(n).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Per Share Purchase Price</u></font>&#8221; equals $1.75, subject to
      adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing Date.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Person</u></font>&#8221; means an individual or corporation,
      partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Placement Agent</u></font>&#8221; means Cantor Fitzgerald &amp; Co.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Pre-Funded Warrant Shares</u></font>&#8221; means the shares of Common
      Stock issuable upon exercise of the Pre-Funded Warrants.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Pre-Funded Warrants</u></font>&#8221; means, collectively, the
      Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, in the form of <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit C</u></font> attached hereto.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Proceeding</u></font>&#8221; means an action, claim, suit,
      investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Public Information Failure Payments</u></font>&#8221; shall have the
      meaning ascribed to such term in Section 4.2(b).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchaser Party</u></font>&#8221; shall have the meaning ascribed to
      such term in Section 4.8.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Rights Agreement</u></font>&#8221; means the Registration
      Rights Agreement, dated on or about the date hereof, among the Company and the Purchasers, substantially in the form of <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit D</u></font> attached hereto.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Statement</u></font>&#8221; means a registration
      statement meeting the requirements set forth in the Registration Rights Agreement and covering the resale by the Purchasers of the Shares and the Warrant Shares.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Required Approvals</u></font>&#8221; shall have the meaning ascribed
      to such term in Section 3.1(e).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rule 144</u></font>&#8221; means Rule 144 promulgated by the
      Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rule 424</u></font>&#8221; means Rule 424 promulgated by the
      Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>SEC Reports</u></font>&#8221; shall have the meaning ascribed to such
      term in Section 3.1(h).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Securities</u></font>&#8221; means the Shares, the Warrants and the
      Warrant Shares.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Securities Act</u></font>&#8221; means the Securities Act of 1933, as
      amended, and the rules and regulations promulgated thereunder.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Shares</u></font>&#8221; means the shares of Common Stock issued or
      issuable to each Purchaser pursuant to this Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Short Sales</u></font>&#8221; means all &#8220;short sales&#8221; as defined in
      Rule 200 of Regulation SHO under the Exchange Act <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(but shall not be deemed to include </font>locating and/or borrowing<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> shares of Common Stock)</font>.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Subscription Amount</u></font>&#8221; means, as to each Purchaser, the
      aggregate amount to be paid for Shares and Warrants purchased hereunder as specified below such Purchaser&#8217;s name on the signature page of this Agreement and next to the heading &#8220;Subscription Amount,&#8221; in United States dollars and in immediately
      available funds (minus, if applicable, a Purchaser&#8217;s aggregate exercise price of the Pre-Funded Warrants, which exercise price shall be paid as and when such Pre-Funded Warrants are exercised).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Subsidiary</u></font>&#8221; means any subsidiary of the Company and
      shall, where applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof.&#160; As of the date of this Agreement, the Company&#8217;s subsidiaries (excluding dormant subsidiaries) are Brooklyn
      ImmunoTherapeutics LLC, a Delaware limited liability company, Novellus, Inc., a Delaware corporation, and Novellus Therapeutics, Ltd., a company formed under the laws of Ireland.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Trading Day</u></font>&#8221; means a day on which the principal
      Trading Market is open for trading.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Trading Market</u></font>&#8221; means any of the following markets or
      exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to
      any of the foregoing).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transaction Documents</u></font>&#8221; means this Agreement, the
      Warrants, the Registration Rights Agreement, the Lock-Up Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transfer Agent</u></font>&#8221; means Computershare Trust Company,
      N.A., the current transfer agent of the Company, and any successor transfer agent of the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Variable Rate Transaction</u></font>&#8221; shall have the meaning
      ascribed to such term in Section 4.11(b).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>VWAP</u></font>&#8221; means, for any date, the price determined by
      the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on
      which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
      price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the
      Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock
      as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrants</u></font>&#8221; means, collectively, the Common Warrants
      and the Pre-Funded Warrants.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant Shares</u></font>&#8221; means the shares of Common Stock
      issuable upon exercise of the Warrants.</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE II.</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PURCHASE AND SALE</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">2.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Closing</u></font>.&#160; On the Closing Date, which date shall be the second Trading Day following the Trading Day immediately following the execution of this Agreement, upon the terms and
        subject to the conditions set forth herein, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to an aggregate of $12 million of Shares and Warrants.&#160; Notwithstanding anything herein to the contrary, to
        the extent that a Purchaser determines, in its sole discretion, that such Purchaser&#8217;s Subscription Amount (together with such Purchaser&#8217;s Affiliates and any Person acting as a group together with such Purchaser or any of such Purchaser&#8217;s
        Affiliates) would cause such Purchaser&#8217;s beneficial ownership of the shares of Common Stock to exceed the Beneficial Ownership Limitation, or as such Purchaser may otherwise choose, such Purchaser may elect to purchase Pre-Funded Warrants in lieu
        of the Shares as determined pursuant to Section 2.2(a). The &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Beneficial Ownership Limitation</u></font>&#8221; shall be 4.99% (or, at the election of the Purchaser at Closing, 9.99%) of
        the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of the Securities on the Closing Date.&#160; In each case, the election to receive Pre-Funded Warrants is solely at the option of the Purchaser. Each
        Purchaser shall deliver to the Company, via wire transfer or a certified check, immediately available funds equal to such Purchaser&#8217;s Subscription Amount as set forth on the signature page hereto executed by such Purchaser, and the Company shall
        deliver to each Purchaser its respective Shares and a Warrant, as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at the Closing.&#160; Upon satisfaction of the
        covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur remotely via the electronic exchange of all closing deliverables, or as the parties shall otherwise mutually agree.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">2.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Deliveries</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">On or prior to the Closing Date,
        the Company shall deliver or cause to be delivered to each Purchaser the following:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">this Agreement duly executed by
        the Company;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">a legal opinion of Company
        Counsel in a form reasonably acceptable to the Purchasers;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">a copy of the irrevocable
        instructions to the Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, a certificate evidencing a number of Shares equal to such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price, registered in
        the name of such Purchaser, or, at the election of such Purchaser, evidence of the issuance of such Purchaser&#8217;s Shares hereunder as held in DRS book-entry form by the Transfer Agent and registered in the name of such Purchaser, which evidence shall
        be reasonably satisfactory to such Purchaser;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">if applicable, a Pre-Funded Warrant
        registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to the difference between (A) such Purchaser&#8217;s Subscription Amount divided by the Per Share Purchase Price and (B) the number of Shares otherwise
        issuable to such Purchaser that would cause such Purchaser&#8217;s beneficial ownership of Common Stock (as calculated by Purchaser, and on which calculation the Company shall be entitled to rely and shall have no obligation to investigate or confirm or
        otherwise have any liability to any Person in respect thereof) to be more than the Beneficial Ownership Limitation with an exercise price equal to $0.005 per share of Common Stock, subject to adjustment therein;</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">a Warrant registered in the name of
        such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the sum of such Purchaser&#8217;s Shares and Pre-Funded Warrant Shares, with an exercise price equal to $1.91, subject to adjustment as set forth therein;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(vi)</font>&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the Company shall have provided
        each Purchaser with the Company&#8217;s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(vii)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the Lock-Up Agreements; and</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(viii)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the Registration Rights Agreement
        duly executed by the Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">On or prior to the Closing Date,
        each Purchaser shall deliver or cause to be delivered to the Company, the following:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">this Agreement duly executed by
        such Purchaser;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">such Purchaser&#8217;s Subscription
        Amount by wire transfer of immediately available funds to the account of the Company specified in writing by the Company; and</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the Registration Rights Agreement
        duly executed by such Purchaser.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">2.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Closing Conditions</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the accuracy in all material
        respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless
        as of a specific date therein in which case they shall be accurate as of such date);</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">all obligations, covenants and
        agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the delivery by each Purchaser of
        the items set forth in Section 2.2(b) of this Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">The respective obligations of the
        Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the accuracy in all material
        respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as
        of a specific date therein in which case they shall be accurate as of such date);</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">all obligations, covenants and
        agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">the delivery by the Company of
        the items set forth in Section 2.2(a) of this Agreement;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iv)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">there shall have been no Material
        Adverse Effect with respect to the Company since the date hereof; and</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">from the date hereof to the Closing
        Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&#8217;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have
        been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New
        York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which,
        in each case, in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing.</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE III.</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">REPRESENTATIONS AND WARRANTIES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">3.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Representations and Warranties of the Company</u></font>. Except as set forth in the SEC Reports and in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof
        and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Subsidiaries</u></font>.&#160; All of the direct and indirect subsidiaries of the Company are set forth in the definition of the term &#8220;Subsidiary&#8221; contained in this Agreement.&#160; The Company owns, directly or
        indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable
        and free of preemptive and similar rights to subscribe for or purchase securities.&#160; If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Organization and Qualification</u></font>.&#160; The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing (if the concept of good standing
        exists in such jurisdiction) under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted.&#160; Neither the
        Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.&#160; Each of the Company and the Subsidiaries is duly
        qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure
        to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect
        on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&#8217;s ability to perform in any material respect on
        a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Material Adverse Effect</u></font>&#8221;) and no Proceeding has been instituted in any such
        jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Authorization; Enforcement</u></font>.&#160; The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement and each of the other
        Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.&#160; The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions
        contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the Board of Directors or the Company&#8217;s stockholders in connection herewith or therewith
        other than in connection with the Required Approvals.&#160; This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the
        terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
        reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and
        (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Conflicts</u></font>.&#160; The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the issuance and sale of the Securities and the
        consummation by it of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company&#8217;s or any Subsidiary&#8217;s certificate or articles of incorporation, bylaws or other organizational or
        charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company or any
        Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument
        (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the
        Required Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including
        federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably be expected to
        result in a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Filings, Consents and Approvals</u></font>.&#160; The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other
        federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this
        Agreement, (ii) the filing with the Commission pursuant to the Registration Rights&#160; Agreement, (iii) the notice and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the Shares and
        Warrant Shares for trading thereon in the time and manner required thereby and (iv) the filing of Form D with the Commission and such filings as are required to be made under applicable state securities laws (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Required Approvals</u></font>&#8221;).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Issuance of the Securities</u></font>.&#160; The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and
        nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents and arising under applicable securities laws.&#160; The Warrant Shares, when issued in accordance with the
        terms of the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than restrictions on transfer provided for in the Transaction Documents.&#160; The Company has reserved
        from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant to this Agreement and the Warrants.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Capitalization</u></font>.&#160; The capitalization of the Company as of the date hereof comprises 100,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.005 per share.&#160; As of the
        date hereof, the Company has 51,951,937 shares of Common Stock outstanding and 156,112 shares of preferred stock outstanding. The Company has not issued any capital stock since its <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">most recently filed periodic report under the Exchange Act, </font>other than pursuant to the exercise of employee stock options under the Company&#8217;s stock option plans, the issuance of shares of Common Stock to employees
        pursuant to the Company&#8217;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act.&#160; No Person has any
        right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents.&#160; Except as a result of the purchase and sale of the Securities and as disclosed in
        the SEC Reports, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or
        giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to
        issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary.&#160; The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or other securities to
        any Person (other than the Purchasers). Except as disclosed in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion, exchange or reset price of
        such security or instrument upon an issuance of securities by the Company or any Subsidiary.&#160; There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar provisions, and there are no
        contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation rights or &#8220;phantom stock&#8221;
        plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance in all material respects with all
        federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities.&#160; No further approval or authorization of any stockholder, the Board
        of Directors or others is required for the issuance and sale of the Securities.&#160; There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#8217;s capital stock to which the Company is a party or, to
        the knowledge of the Company, between or among any of the Company&#8217;s stockholders.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>SEC Reports; Financial Statements</u></font>.&#160; The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange
        Act, including pursuant to Section 13(a) or 15(d) thereof, for the two (2) years immediately preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials,
        including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>SEC Reports</u></font>&#8221;) on a timely basis or has
        received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension.&#160; As of their respective dates, the SEC Reports complied in all material respects with the requirements of the
        Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the
        statements therein, in the light of the circumstances under which they were made, not misleading.&#160; The Company has never been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC
        Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing.&#160; Such financial statements have been prepared in accordance
        with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>GAAP</u></font>&#8221;), except as may be otherwise specified in
        such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated
        Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Material Changes; Undisclosed Events, Liabilities or Developments</u></font>.&#160; Since the date of the latest audited financial statements included within the SEC Reports, except as disclosed in a subsequent SEC
        Report filed or furnished prior to the date hereof, (i) there has been no event, occurrence or development that has had or that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities
        (contingent or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not required to be reflected in the Company&#8217;s financial statements pursuant
        to GAAP or disclosed in filings made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased,
        redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company stock option plans.&#160; The
        Company does not have pending before the Commission any request for confidential treatment of information.&#160; Except for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development
        has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be
        disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Litigation</u></font>.&#160; Except as disclosed in the SEC Reports, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
        against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Action</u></font>&#8221;), which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were
        an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.&#160; Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of
        or liability under federal or state securities laws or a claim of breach of fiduciary duty, which would, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.&#160; There has not been, and to the
        knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company.&#160; The Commission has not issued any stop order or other order
        suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Labor Relations</u></font>.&#160; No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a
        Material Adverse Effect.&#160; None of the Company&#8217;s or its Subsidiaries&#8217; employees is a member of a union that relates to such employee&#8217;s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party
        to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good.&#160; To the knowledge of the Company, no executive officer of the Company or any Subsidiary is, or is now
        expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of
        any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters.&#160; The Company and its Subsidiaries are in compliance
        with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in
        the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Compliance</u></font>.&#160; Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would
        result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other agreement
        or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree, or order of any court, arbitrator or other governmental
        authority or (iii) is in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health
        and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(m)</font>&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';">&#160; <u>Environmental Laws</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the
        environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous
        substances or wastes (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Hazardous Materials</u></font>&#8221;) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment,
        storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations, issued,
        entered, promulgated or approved thereunder (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Environmental Laws</u></font>&#8221;); (ii) have received all permits licenses or other approvals required of them under applicable
        Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply could be reasonably
        expected to have, individually or in the aggregate, a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(n)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Regulatory Permits</u></font>.&#160; The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local or foreign regulatory authorities necessary
        to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Material Permits</u></font>&#8221;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Title to Assets</u></font>.&#160; The Company and the Subsidiaries have good and marketable title in fee simple to or have valid rights to lease or otherwise use all real property that is described in the SEC
        Reports and have good and marketable title in or valid rights to lease or otherwise use all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for
        (i) Liens as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii) Liens for the payment of federal, state or
        other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and the payment of which is neither delinquent nor subject to penalties.&#160; Any real property and facilities held under lease by the Company and the
        Subsidiaries are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in material compliance.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(p)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Intellectual Property</u></font>.&#160; The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets,
        inventions, copyrights, licenses and other intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a
        Material Adverse Effect (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Intellectual Property Rights</u></font>&#8221;).&#160; None of, and neither the Company nor any Subsidiary has received a notice (written or
        otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.&#160; Neither the Company nor any Subsidiary
        has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any
        Person, except as could not have or reasonably be expected to not have a Material Adverse Effect.&#160; To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
        of the Intellectual Property Rights.&#160; The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not,
        individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(q)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Insurance</u></font>.&#160; The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the
        businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate Subscription Amount.&#160; Neither the Company nor any Subsidiary has any reason
        to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(r)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transactions with Affiliates and Employees</u></font>.&#160; Except as disclosed in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of
        the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
        providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or
        such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000
        other than for (i) payment of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under any stock option plan of the
        Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(s)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Sarbanes-Oxley; Internal Accounting Controls</u></font>.&#160; The Company and the Subsidiaries are in compliance in all material respects with any and all applicable requirements of the Sarbanes-Oxley Act of 2002
        that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with management&#8217;s general or
          specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with
          management&#8217;s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company and the
          Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information
          required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms.&#160; The Company&#8217;s certifying
          officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date, the &#8220;<u>Evaluation



            Date</u>&#8221;).&#160; The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of
          the Evaluation Date.&#160; Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or are
          reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries.</font></font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(t)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Certain Fees</u></font>.&#160; Except for fees payable to the Placement Agent and Maxim Group in respect of the transactions contemplated by the Transaction Documents, no brokerage or finder&#8217;s fees or commissions
        are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents.&#160;
        The Purchasers shall have no obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by
        the Transaction Documents.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(u)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Private Placement</u></font>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the
        Securities by the Company to the Purchasers as contemplated hereby. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(v)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Investment Company</u></font>. The Company is not required to be registered as, and, immediately after receipt of payment for the Securities, will not be required to be registered as, an &#8220;investment company&#8221;
        within the meaning of the Investment Company Act of 1940, as amended.&#160; The Company shall conduct its business in a manner so that it will not become required to be registered as an &#8220;investment company&#8221; subject to registration under the Investment
        Company Act of 1940, as amended.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(w)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Rights</u></font>.&#160; Other than each of the Purchasers and except as disclosed in the SEC Reports, no Person has any right to cause the Company or any Subsidiary to effect the registration under the
        Securities Act of any securities of the Company or any Subsidiary.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(x)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Listing and Maintenance Requirements</u></font>.&#160; The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no action designed to, or which to its
        knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.&#160; The Company has
        not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of
        such Trading Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements. The Common Stock is currently eligible for electronic
        transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in connection with such
        electronic transfer.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(y)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Application of Takeover Protections</u></font>.&#160; The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business
        combination, poison pill (including any distribution under a rights agreement) or other similar anti&#8209;takeover provision under the Company&#8217;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that
        is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#8217;s
        issuance of the Securities and the Purchasers&#8217; ownership of the Securities.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(z)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Disclosure</u></font>.&#160; Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting
        on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might constitute material, non-public information.&#160;&#160; The Company understands and confirms that the Purchasers will rely
        on the foregoing representation in effecting transactions in securities of the Company.&#160; All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and
        the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
        statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any
        untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading.&#160;
        The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><a name="z_Toc430524909"></a><a name="z_Toc449254780"></a><font style="font-size: 10pt; font-family: 'Times New Roman';">(aa)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Integrated Offering</u></font>. Assuming the accuracy of the Purchasers&#8217; representations and warranties set forth in Section 3.2, neither the
        Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering
        of the Securities to be integrated with prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any such securities under the Securities Act, or (ii) any applicable shareholder approval
        provisions of any Trading Market on which any of the securities of the Company are listed or designated.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(bb)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Solvency</u></font><a name="z_DV_C40"></a>.&#160; Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the proceeds from the sale
        of the Securities hereunder, (i) the fair saleable value of the Company&#8217;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#8217;s existing debts and other liabilities (including known contingent liabilities) as
        they mature, (ii) the Company&#8217;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the
        business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of
        its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid.&#160; The Company does not intend to incur debts beyond its
        ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt).&#160; The Company has no knowledge of any facts or circumstances which lead it to believe that it will file for
        reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date.&#160; The SEC Reports set forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company
        or any Subsidiary, or for which the Company or any Subsidiary has commitments.&#160; For the purposes of this Agreement, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indebtedness</u></font>&#8221; means (x) any liabilities for borrowed
        money or amounts owed in excess of $100,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or not the
        same are or should be reflected in the Company&#8217;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and
        (z) the present value of any lease <a name="z_Toc497644622"></a>payments in excess of $100,000 due under leases required to be capitalized in accordance with GAAP.&#160; Neither the Company nor any Subsidiary is in default with respect to any
        Indebtedness.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(cc)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Tax Status</u></font>.&#160; Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i) has
        made or filed all United States federal, state and local income and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental
        assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations, except for taxes, if any, as are being contested in good faith and as to which adequate reserves have been established by
        the Company and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply.&#160; There are no unpaid taxes in any
        material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(dd)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No General Solicitation</u></font>.&#160; Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities by any form of general solicitation or general advertising.&#160; The
        Company has offered the Securities for sale only to the Purchasers and certain other &#8220;accredited investors&#8221; within the meaning of Rule 501 under the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ee)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Foreign Corrupt Practices.</u></font>&#160; Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary,
        has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials
        or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company
        is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ff)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Accountants</u></font>.&#160; The Company&#8217;s accounting firm is Marcum LLP.&#160; To the knowledge and belief of the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act
        and (ii) shall express its opinion with respect to the financial statements to be included in the Company&#8217;s Annual Report for the fiscal year ended December 31, 2021.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(gg)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Disagreements with Accountants and Lawyers</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;There are no material disagreements of any kind presently existing, or reasonably anticipated by the Company to arise, between the Company and
        the accountants and lawyers formerly or presently employed by the Company, which would reasonably be expected to affect the Company&#8217;s ability to perform any of its obligations under any of the Transaction Documents, and the Company is current with
        respect to any fees owed to its accountants and lawyers.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(hh)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Acknowledgment Regarding Purchasers&#8217; Purchase of Securities</u></font>.&#160; The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#8217;s length purchaser with
        respect to the Transaction Documents and the transactions contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the
        Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is
        merely incidental to the Purchasers&#8217; purchase of the Securities.&#160; The Company further represents to each Purchaser that the Company&#8217;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent
        evaluation of the transactions contemplated hereby by the Company and its representatives.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>Acknowledgment Regarding Purchaser&#8217;s Trading Activity.</u>&#160; Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections 3.2(g) and 4.13 hereof), it
          is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or
          &#8220;derivative&#8221; securities based on securities issued by the Company or to hold the Securities for any specified term, (ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or
          &#8220;derivative&#8221; transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&#8217;s publicly-traded securities, (iii) any Purchaser, and counter-parties in &#8220;derivative&#8221;
          transactions to which any such Purchaser is a party, directly or indirectly, presently may have a &#8220;short&#8221; position in the Common Stock and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm&#8217;s length
          counter-party in any &#8220;derivative&#8221; transaction.&#160; </font>The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding,
        including, without limitation, during the periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of the existing stockholders&#8217; equity
        interests in the Company at and after the time that the hedging activities are being conducted.&#160; The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(jj)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Regulation M Compliance.</u></font>&#160; The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action designed to cause or to result in the stabilization
        or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or
        agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Company&#8217;s placement agent in connection with the
        placement of the Securities.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(kk)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Form S-3 Eligibility</u></font>.&#160; Upon the timely filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021, the Company expects to be eligible to register the resale of the
        Securities for resale by the Purchaser on Form S-3 promulgated under the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ll)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Stock Option Plans</u></font>. Each stock option granted by the Company under the Company&#8217;s stock option plan was granted (i) in accordance with the terms of the Company&#8217;s stock option plan and (ii) with an
        exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&#8217;s stock option plan has been backdated.&#160;
        The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public
        announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(mm)</font>&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Cybersecurity</u></font>.&#160; (i)(x) To the Company&#8217;s knowledge, <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">t</font>here has been no security breach or other compromise of
        or relating to any of the Company&#8217;s or any Subsidiary&#8217;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data
        maintained by or on behalf of it), equipment or technology (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>IT Systems and Data</u></font>&#8221;) and (y) the Company and the Subsidiaries have not been notified of, and
        has no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are presently in compliance with all applicable
        laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to
        the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have
        implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the
        Subsidiaries have implemented backup and disaster recovery technology consistent with customary industry standards and practices.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(nn)</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Office of Foreign Assets Control</u></font>.&#160; Neither the Company nor any Subsidiary nor, to the Company&#8217;s knowledge, any director, officer, agent, employee or affiliate of the Company or any Subsidiary is
        currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>OFAC</u></font>&#8221;).</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(oo)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>U.S. Real Property Holding Corporation</u></font>.&#160; The Company is not and has never been a U.S. real property holding corporation within the meaning of Section 897 of the Internal Revenue Code of 1986, as
        amended.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(pp)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Bank Holding Company Act</u></font>.&#160; Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>BHCA</u></font>&#8221;) and to regulation by the Board of Governors of the Federal Reserve System (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Federal Reserve</u></font>&#8221;).&#160; Neither the
        Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank or any
        entity that is subject to the BHCA and to regulation by the Federal Reserve.&#160; Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to
        the BHCA and to regulation by the Federal Reserve.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(qq)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Money Laundering</u></font>.&#160; The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable financial record-keeping and reporting requirements of the
        Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Money
            Laundering Laws</u></font>&#8221;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Money Laundering Laws is pending or, to the
        knowledge of the Company or any Subsidiary, threatened.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(rr)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Disqualification Events</u></font>.&#160; With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any
        affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities, calculated on the basis of voting
        power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Issuer Covered Person</u></font>&#8221;
        and, together, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Issuer Covered Persons</u></font>&#8221;) is subject to any of the &#8220;Bad Actor&#8221; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Disqualification Event</u></font>&#8221;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer
        Covered Person is subject to a Disqualification Event. The Company has complied, to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ss)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Other Covered Persons</u></font>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly or indirectly)
        remuneration for solicitation of purchasers in connection with the sale of any Securities.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(tt)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notice of Disqualification Events</u></font>. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing Date of (i) any Disqualification Event relating to any Issuer
        Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating to any Issuer Covered Person.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">3.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Representations and Warranties of the Purchasers</u></font>.&#160; Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof and as of the
        Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Organization; Authority</u></font>.&#160; Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its
        incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its
        obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
        partnership, limited liability company or similar action, as applicable, on the part of such Purchaser.&#160; Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance
        with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
        reorganization, moratorium and other laws of general application affecting enforcement of creditors&#8217; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and
        (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Own Account</u></font>.&#160; Such Purchaser understands that the Securities are &#8220;restricted securities&#8221; and have not been registered under the Securities Act or any applicable state securities law and is acquiring
        the Securities as principal for its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of
        distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such
        Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&#8217;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with
        applicable federal and state securities laws).&#160; Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">23</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchaser Status</u></font>.&#160; At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i) an
        &#8220;accredited investor&#8221; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii) a &#8220;qualified institutional buyer&#8221; as defined in Rule 144A(a) under the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font>&#160; &#160; &#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Experience of Such Purchaser</u></font>.&#160; Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be
        capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment.&#160; Such Purchaser is able to bear the economic risk of an investment in the Securities and, at
        the present time, is able to afford a complete loss of such investment.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>General Solicitation</u></font>.&#160; Such Purchaser is not, to such Purchaser&#8217;s knowledge, purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the
        Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><a name="z_DV_C18"></a><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Access to Information</u></font>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the
        SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the
        merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and
        (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.&#160; Such Purchaser
        acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser with any information or advice with respect to the Securities nor is such information or advice necessary or desired.&#160;
        Neither the Placement Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent and any Affiliate may have acquired non-public information with respect to the Company
        which such Purchaser agrees need not be provided to it.&#160; In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or fiduciary to such Purchaser.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">24</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>Certain Transactions and Confidentiality</u>.&#160; Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to
          any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of</font> the time that such Purchaser first received a term
        sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof<a name="z_DV_M122"></a>.&#160;
        Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and the portfolio managers have no direct knowledge of the
        investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the
        investment decision to purchase the Securities covered by this Agreement.&#160; Other than to other Persons party to this Agreement or to such Purchaser&#8217;s representatives, including, without limitation, its officers, directors, partners, legal and other
        advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).&#160; Notwithstanding the foregoing,
        for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser&#8217;s right to rely on the
      Company&#8217;s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or
      the consummation of the transactions contemplated hereby.&#160; Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or
      borrowing shares in order to effect Short Sales or similar transactions in the future.</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE IV.</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">OTHER AGREEMENTS OF THE PARTIES</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.1</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>Transfer Restrictions</u>.</font></font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">The Securities may only be
        disposed of in compliance with state and federal securities laws.&#160; In connection with any transfer of Securities other than pursuant to an effective registration statement, to the Company or to an Affiliate of a Purchaser or in connection with a
        pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion
        shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act.&#160; As a condition of transfer, any such transferee shall agree in writing to be
        bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights and obligations of a Purchaser under this Agreement and the Registration Rights Agreement.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">25</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">The Purchasers agree to the
        imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following form:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS SECURITY HAS NOT BEEN&#160; REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN
      EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
      EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&#160; THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A
      REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#8220;ACCREDITED INVESTOR&#8221; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a
      registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an &#8220;accredited investor&#8221; as defined in Rule 501(a) under the Securities Act and, if required under the terms of such
      arrangement, such Purchaser may transfer pledged or secured Securities to the pledgees or secured parties.&#160; Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the pledgee, secured party
      or pledgor shall be required in connection therewith.&#160; Further, no notice shall be required of such pledge.&#160; At the appropriate Purchaser&#8217;s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured party of
      Securities may reasonably request in connection with a pledge or transfer of the Securities, including, if the Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required prospectus
      supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">26</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Certificates evidencing the Shares
        and Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof), (i) while a registration statement (including the Registration Statement) covering the resale of such security is effective under the
        Securities Act, (ii) following any sale of such Shares or Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants), (iii) if such Shares or Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of
        the Warrants) without the need to comply with the current information requirement contained in Rule 144(c), or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and
        pronouncements issued by the staff of the Commission).&#160; The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser if required by the Transfer Agent to effect the removal of the legend hereunder, or if
        requested by a Purchaser, respectively.&#160; If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the Warrant Shares, or if such Shares or Warrant Shares may be sold under
        Rule 144 and the Company is then in compliance with the current public information required under Rule 144 (assuming cashless exercise of the Warrants), or if the Shares or Warrant Shares may be sold under Rule 144 without the requirement for the
        Company to be in compliance with the current public information required under Rule 144 as to such Shares or Warrant Shares or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial
        interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends. The Company agrees that at such time as such legend is no longer required under this Section 4.1(c), it will, no
        later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate
        representing Shares or Warrant Shares, as the case may be, issued with a restrictive legend, together with customary representation letters duly executed by such Purchaser (such date, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Legend Removal Date</u></font>&#8221;), deliver or cause to be delivered to such Purchaser a certificate (or book entry with the Transfer Agent) representing such shares that is free from all restrictive and other legends.&#160; The Company may
        not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4.&#160; Certificates for Securities subject to legend removal hereunder shall be transmitted by the
        Transfer Agent to the Purchaser by crediting the account of the Purchaser&#8217;s prime broker with the Depository Trust Company System as directed by such Purchaser.&#160; As used herein, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Standard



            Settlement Period</u></font>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate
        representing Shares or Warrant Shares, as the case may be, issued with a restrictive legend.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">In addition to such Purchaser&#8217;s
        other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated damages and not as a penalty, for each $1,000 of Shares or Warrant Shares (based on the VWAP of the Common Stock on the date such Securities are
        submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day (increasing to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading
        Day after the Legend Removal Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a certificate representing the
        Securities so delivered to the Company by such Purchaser that is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction or otherwise) shares of Common Stock to
        deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that such
        Purchaser anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such Purchaser&#8217;s total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares
        of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any) (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"><u>Buy-In Price</u></font>&#8221;) over the product of (A)
        such number of Shares or Warrant Shares that the Company was required to deliver to such Purchaser by the Legend Removal Date multiplied by (B) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the
        date of the delivery by such Purchaser to the Company of the applicable Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this Section 4(d).</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">27</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Each Purchaser, severally and not
        jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an
        exemption therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from
        certificates representing Securities as set forth in this Section 4.1 is predicated upon the Company&#8217;s reliance upon this understanding.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Furnishing of Information; Public Information</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Until the earlier of the time that (i) no Purchaser
        owns Securities or&#160; (ii) the Warrants have expired, the Company covenants to maintain the registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect thereof and file within
        the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">At any time during the period commencing from the six
        (6) month anniversary of the date hereof and ending at such time that all of the Securities may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation pursuant to Rule
        144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c) or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail
        to satisfy any condition set forth in Rule 144(i)(2) (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Public Information Failure</u></font>&#8221;) then, in addition to such Purchaser&#8217;s other available remedies, the Company shall pay
        to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Securities, an amount in cash equal to one percent (1.0%) of the aggregate Subscription Amount of
        such Purchaser&#8217;s Securities on the day of a Public Information Failure and on every thirtieth (30<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure
        is cured and (b) such time that such public information is no longer required&#160; for the Purchasers to transfer the Shares and Warrant Shares pursuant to Rule 144.&#160; The payments to which a Purchaser shall be entitled pursuant to this Section 4.2(b)
        are referred to herein as &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Public Information Failure Payments</u></font>.&#8221;&#160; Public Information Failure<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Payments shall be paid on the earlier of (i) the last day of the calendar month during which such Public Information Failure<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Payments are
        incurred and (ii) the third (3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup>) Business Day after the event or failure giving rise to the Public Information Failure<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Payments is cured.&#160; In the
        event the Company fails to make Public Information Failure<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Payments in a timely manner, such Public Information Failure<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160;</font>Payments shall bear interest at the rate of one percent (1.0%) per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser&#8217;s right to pursue
        actual damages for the Public Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">28</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Integration</u></font>.&#160; The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities
        Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities for
        purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.4</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Securities Laws Disclosure; Publicity</u></font>.&#160; The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated
        hereby, and (b) file a Current Report on Form 8-K, including copies of the Transaction Documents (or the forms thereof) as exhibits thereto, with the Commission within the time required by the Exchange Act.&#160; From and after the issuance of such
        press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers,
        directors, employees or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or
        similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchasers or any of
        their Affiliates on the other hand, shall terminate. The Company and each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser
        shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press
        release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
        or communication.&#160; Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the
        prior written consent of such Purchaser, except (a) as required by federal securities law in connection with (i) any registration statement contemplated by the Registration Rights Agreement and (ii) the filing of final Transaction Documents with
        the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>&#160;</u></font>Company shall provide the Purchasers with prior
        notice of such disclosure permitted under this clause (b).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Shareholder Rights Plan</u></font>.&#160; No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Acquiring Person</u></font>&#8221; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or
        arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other
        agreement between the Company and the Purchasers.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">29</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Non-Public Information</u></font>.&#160; Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents and any material non-public
        information set forth on the Disclosure Schedules, which material terms and conditions and material non-public information shall be disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on
        its behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser shall have consented to the
        receipt of such information and agreed with the Company to keep such information confidential.&#160; The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the
        Company.&#160; To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser without such Purchaser&#8217;s consent, the
        Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to the Company,
        any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the
        extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission
        pursuant to a Current Report on Form 8-K.&#160; The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Use of Proceeds</u></font>.&#160; The Company shall use the net proceeds from the sale of the Securities hereunder for working capital and general corporate purposes and shall not use such
        proceeds: (a)&#160; for the satisfaction of any portion of the Company&#8217;s debt (other than payment of trade payables in the ordinary course of the Company&#8217;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock
        Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">30</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%31%%%-->
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.8</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnification of Purchasers</u></font>.&#160;&#160; Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers, shareholders,
        members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
        of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
        notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchaser Party</u></font>&#8221;) harmless from any and all losses, liabilities,
        obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#8217; fees and costs of investigation that any such Purchaser Party may suffer or incur as a
        result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any
        capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents (unless such action is
        solely based upon a material breach of such Purchaser Party&#8217;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such stockholder or any violations by
        such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct).&#160; If any action shall be brought against any
        Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own
        choosing reasonably acceptable to the Purchaser Party.&#160; Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
        of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or
        (iii) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the
        reasonable fees and expenses of no more than one such separate counsel.&#160; The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&#8217;s prior written consent,
        which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#8217;s breach of any of the representations, warranties, covenants or
        agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents.<a name="z_Toc430524929"></a><a name="z_Toc449254796"></a>&#160; The indemnification required by this Section 4.8 shall be made by periodic payments of the
        amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against
        the Company or others and any liabilities the Company may be subject to pursuant to law.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Reservation of Common Stock</u></font>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive
        rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and Warrant Shares pursuant to any exercise of the Warrants.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>L</u></font><a name="z_Toc430524930"></a><a name="z_Toc449254797"></a><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>isting of Common Stock</u></font>. The Company
        hereby agrees to use reasonable best efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the
        Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading
        Market, it will then include in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as
        possible.&#160; The Company will then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all material respects with the Company&#8217;s reporting, filing and other obligations
        under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without
        limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">31</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>Subsequent
          Equity Sales.</u></font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">From the date hereof until sixty
        (60) days after the Effective Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any
        registration statement or any amendment or supplement thereto, in each case other than as contemplated pursuant to the Registration Rights Agreement</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">From the date hereof until the
        twelve (12) months after the Closing, the Company shall be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of
        units thereof) involving a Variable Rate Transaction.&#160; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Variable Rate Transaction</u></font>&#8221; means a transaction in which the Company (i) issues or sells any debt or equity
        securities that are convertible into, exchangeable or exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or
        varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some
        future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or
        effects a transaction under, any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined price (which, for the elimination of doubt, does not include an &#8220;at the market&#8221;
        offering program).&#160; Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Notwithstanding the foregoing,
        this Section 4.11 shall not apply in respect of an Exempt Issuance or, subsequent to sixty (60) days after the Effective Date, an &#8220;at the market&#8221; offering program, except that no Variable Rate Transaction shall be an Exempt Issuance.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.12</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Equal Treatment of Purchasers</u></font>.&#160; No consideration (including any modification of this Agreement) shall be offered or paid to any Person to amend or consent to a waiver or
        modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement.&#160; For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the Company
        and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or
        voting of Securities or otherwise.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">32</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.13</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>Certain Transactions and Confidentiality</u>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it, nor any Affiliate acting on its behalf or
          pursuant to any understanding with it will execute any purchases or sales, including Short Sales, of any of the Company&#8217;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions
          contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Each Purchaser, severally
          and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser
          will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules.&#160; N</font>otwithstanding the foregoing and notwithstanding anything contained in this Agreement to the
        contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the
        transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the
        Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser
        shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.4.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s assets and
          the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s assets, the covenant set forth above shall only apply with respect to the portion of assets
          managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.</font></font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.14</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Form D; Blue Sky Filings</u></font>.&#160; The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to provide a copy thereof, promptly
        upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under applicable
        securities or &#8220;Blue Sky&#8221; laws of the states of the United States<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>, and shall provide evidence of such actions promptly upon request of any Purchaser</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.15</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Acknowledgment of Dilution</u></font>.&#160; The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may
        be substantial under certain market conditions.&#160; The Company further acknowledges that its obligations under the Transaction Documents, including, without limitation, its obligation to issue the Shares and Warrant Shares pursuant to the Transaction
        Documents, are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of any such dilution or any claim the Company may have against any Purchaser and regardless of the
        dilutive effect that such issuance may have on the ownership of the other stockholders of the Company.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">33</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.16</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise Procedures</u></font>.&#160; The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the
        Warrants.&#160; No additional legal opinion, other information or instructions shall be required of the Purchasers to exercise their Warrants.&#160; Without limiting the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any
        medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants.&#160; The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with
        the terms, conditions and time periods set forth in the Transaction Documents.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">4.17</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Lock-Up Agreements</u></font>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend the term of the lock-up period and
        shall enforce the provisions of each Lock-Up Agreement in accordance with its terms.&#160; If any party to a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use its reasonable best efforts to seek specific
        performance of the terms of such Lock-Up Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ARTICLE V.</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">MISCELLANEOUS</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.1</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Termination</u></font>.&#160; This Agreement may be terminated by any Purchaser, as to such Purchaser&#8217;s obligations hereunder only and without any effect whatsoever on the obligations between
        the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before the fifth (5<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Trading Day following the date hereof; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.2</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Fees and Expenses</u></font>.&#160; Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel,
        accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement.&#160; The Company shall pay all Transfer Agent fees (including, without
        limitation, any fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any
        Securities to the Purchasers (exclusing any successors or assigns thereof).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.3</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Entire Agreement</u></font>.&#160; The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect to the subject
        matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">34</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.4</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notices</u></font>.&#160; Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective
        on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30
        p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the
        signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c) the second (2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>) Trading Day following the date of mailing, if sent by U.S. nationally recognized
        overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given.&#160; The address for such notices and communications shall be as set forth on the signature pages attached hereto.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.5</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Amendments; Waivers</u></font>.&#160; No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of an amendment, by
        the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against
        whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at least 50.1% in interest (based on the
        initial Subscription Amounts hereunder) of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required.&#160; No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be
        deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
        impair the exercise of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers
        shall require the prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.6</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Headings</u></font>.&#160; The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.7</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successors and Assigns</u></font>.&#160; This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.&#160; The Company may not assign
        this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger).&#160; Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns
        or transfers any Securities in accordance with the terms of this Agreement and the applicable Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction
        Documents that apply to the &#8220;Purchasers.&#8221;</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.8</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Third-Party Beneficiaries</u></font>.&#160; The Placement Agent shall be the third-party beneficiary of the representations and warranties of the Company in Section 3.1 and the
        representations and warranties of the Purchasers in Section 3.2.&#160; This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be
        enforced by, any other Person, except as otherwise set forth in Section 4.8 and this Section 5.8.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">35</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.9</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Governing Law</u></font>.&#160; All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and
        enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof that would result in the application of the laws of any jurisdiction other than the State of new York.&#160; Each party
        agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
        directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.&#160; Each party hereby irrevocably submits to the exclusive jurisdiction of the
        state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the
        enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding
        is improper or is an inconvenient venue for such Proceeding.&#160; Each party hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or
        certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.&#160;
        Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law.&#160;&#160; If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in
        addition to the obligations of the Company under Section 4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&#8217; fees and other costs and expenses incurred with the
        investigation, preparation and prosecution of such Action or Proceeding.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.10</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Survival</u></font>.&#160; The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.11</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Execution</u></font>.&#160; This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become
        effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same counterpart.&#160; In the event that any signature is delivered by facsimile transmission or by
        e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature
        page were an original thereof.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.12</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severability</u></font>.&#160; If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable,
        the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable
        efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that
        they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">36</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.13</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rescission and Withdrawal Right</u></font>.&#160; Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction
        Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or
        withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that, in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return
        any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#8217;s right to acquire
        such shares pursuant to such Purchaser&#8217;s Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.14</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Replacement of Securities</u></font>.&#160; If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued
        in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such
        loss, theft or destruction.&#160; The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.15</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Remedies</u></font>.&#160; In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and the Company will
        be entitled to specific performance under the Transaction Documents.&#160; The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and
        hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.16</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Payment Set Aside</u></font>.&#160; To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces or exercises its
        rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to
        be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent
        of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">37</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.17</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Independent Nature of Purchasers&#8217; Obligations and Rights</u></font>.&#160; The obligations of each Purchaser under any Transaction Document are several and not joint with the obligations of
        any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance of the obligations of any other Purchaser under any Transaction Document.&#160; Nothing contained herein or in any other Transaction Document,
        and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
        acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents.&#160; Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the
        rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.&#160; Each Purchaser has been represented by
        its own separate legal counsel in its review and negotiation of the Transaction Documents.&#160; The Company has elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was
        required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between
        the Company and the Purchasers collectively and not between and among the Purchasers.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.18</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Liquidated Damages</u></font>.&#160; The Company&#8217;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents is a continuing obligation of the
        Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due and
        payable shall have been canceled.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.19</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>Saturdays, Sundays, Holidays, etc.</u></font>If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
        shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.20</font>&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Construction</u></font>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents and, therefore, the
        normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference
        to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the
        date of this Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">5.21</font>&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;"><u>WAIVER OF JURY TRIAL</u>.&#160; <u>IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND
            INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.</u></font></font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">38</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%39%%%-->
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Signature Pages Follow)</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">39</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
      as of the date first indicated above.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z56620de57b6e49898601dac1682e2198" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
          </td>
          <td style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><u>Address for Notice:</u></div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">10531 4S Commons Drive</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Suite 166-550</div>
          </td>
        </tr>
        <tr>
          <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">San Diego, California 92127</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 3%; vertical-align: top; padding-bottom: 2px;">By:</td>
          <td rowspan="1" style="width: 42%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Howard J. Federoff</font></td>
          <td rowspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Email:</div>
          </td>
        </tr>
        <tr>
          <td style="vertical-align: top;"> <br>
          </td>
          <td style="vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name: Howard J. Federoff</div>
          </td>
          <td style="width: 5%; vertical-align: top;"><br>
          </td>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">hfederoff@brooklynitx.com</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title: President and Chief Executive Officer</div>
          </td>
          <td rowspan="1" style="width: 5%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">With a copy to (which shall not constitute notice):</div>
          </td>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td colspan="2" style="vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Greenberg Traurig, P.A.</div>
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">333 S.E. 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Avenue, Suite 4400</div>
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Miami, FL 33131</div>
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Attn:&#160; Drew M. Altman</div>
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Email:&#160; ltmand@gtlaw.com</div>
          </td>
          <td style="vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">40</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as
      of the date first indicated above.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" id="z8f2ae9ea77474dd1b9ed8104faf561c0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 15%; padding-bottom: 2px;">
              <div>Name of Purchaser:</div>
            </td>
            <td style="width: 85%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="margin-left: 9pt"><font style="font-size: 10pt; font-family: 'Times New Roman';">Armistice Capital Master Fund Ltd.</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 35%; padding-bottom: 2px;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Signature of Authorized Signatory of Purchaser</font>: </td>
            <td style="width: 65%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Steven Boyd</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 22%; padding-bottom: 2px;">Name of Authorized Signatory: </td>
            <td style="width: 78%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="margin-left: 9pt"><font style="font-size: 10pt; font-family: 'Times New Roman';">Steven Boyd</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 22%; padding-bottom: 2px;">Title of Authorized Signatory:</td>
            <td style="width: 78%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="margin-left: 9pt"><font style="font-size: 10pt; font-family: 'Times New Roman';">CIO of Armistice Capital, LLC, the Investment Manager</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
  </div>
  <div>Email Address of Authorized Signatory: REDACTED
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Address for Notice to Purchaser: REDACTED</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Address for Delivery of Securities to Purchaser (if not same as address for notice): REDACTED</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z46cd3bbf677e4878a24423ad4aa3a5eb" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 17%; padding-bottom: 2px;">
              <div>Subscription Amount: $</div>
            </td>
            <td style="width: 18%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 65%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 7%; padding-bottom: 2px;">Shares: </td>
            <td style="width: 13%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 80%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 18%; padding-bottom: 2px;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Pre-Funded Warrants:</font></td>
            <td style="width: 17%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 5%; padding-bottom: 2px;">&#160;</td>
            <td style="width: 60%; padding-bottom: 2px;">
              <div><font style="font-size: 10pt; font-family: 'Times New Roman';">Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</font></div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 16%; padding-bottom: 2px;">
              <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Common Warrants:</font></div>
            </td>
            <td style="width: 19%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 5%; padding-bottom: 2px;">&#160;</td>
            <td style="width: 60%; padding-bottom: 2px;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99%</font></td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 10%; padding-bottom: 2px;">EIN Number </td>
            <td style="width: 17%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 73%; padding-bottom: 2px;"><br>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE PAGES CONTINUE]</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">41</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Exhibit A</u></div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">[Form of Common Warrants &#8211; Attached]</div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Exhibit B</u></div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">[Form of Lock-Up Agreement &#8211; Attached]</div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Exhibit C</u></div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">[Form of Pre-Funded Warrants &#8211; Attached]</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Exhibit D</u></div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">[Form of Registration Rights Agreement &#8211; Attached]</div>
    <div><br>
    </div>
  </div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>brhc10034972_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="font-weight: bold; text-align: right;">Exhibit 10.2<br>
    </div>
    <div>
      <div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
      </div>
    </div>
  </div>
  <div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
      COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
      SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&#160; THIS SECURITY AND THE SECURITIES ISSUABLE
      UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PRE-FUNDED COMMON STOCK PURCHASE WARRANT</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z963840108a774547b4dcc459406b2ed0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 70%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Warrant Shares:&#160; 1,357,142</div>
          </td>
          <td style="width: 30%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Issue Date: March 9, 2022</div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant</u></font>&#8221;) certifies
      that, for value received, Armistice Capital Master Fund Ltd. or its assigns (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Holder</u></font>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the
      conditions hereinafter set forth, at any time on or after the date hereof (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Initial Exercise Date</u></font>&#8221;) until this Warrant is exercised in full&#160; (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Termination Date</u></font>&#8221;) but not thereafter, to subscribe for and purchase from Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), up to 1,357,142 shares (as subject to adjustment hereunder, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant Shares</u></font>&#8221;) of Common Stock.&#160; The purchase
      price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 1</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Definitions</u></font>.&#160; Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchase Agreement</u></font>&#8221;), dated March 6, 2022, among the Company and the purchasers signatory thereto.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 2</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise of Warrant</u></font>.&#160; Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the
        Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notice of Exercise</u></font>&#8221;).&#160; Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as
        aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank,&#160; unless the cashless exercise procedure
        specified in Section 2(c) below is specified in the applicable Notice of Exercise.&#160; No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be
        required.&#160; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been
        exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant
        resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant
        Shares purchased.&#160; The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of
        receipt of such notice. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph,
          following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise Price</u></font>.&#160; The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.005 per Warrant Share, was pre-funded to the Company on or prior to the Initial Exercise Date
        and, consequently, no additional consideration (other than the nominal exercise price of $0.005 per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant.&#160; The Holder shall not be entitled to
        the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever. The remaining unpaid exercise price per share of Common Stock under this Warrant shall be $0.005, subject to
        adjustment as set forth herein (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise Price</u></font>&#8221;).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Cashless Exercise</u></font>.&#160; This Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares
        equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -36pt; margin-left: 108pt;">(A) =&#160;&#160;&#160; as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if
      such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading
      hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
      of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Bloomberg</u></font>&#8221;) as of the time of the Holder&#8217;s execution of
      the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a
      Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
      2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: -36pt; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: -31.5pt; margin-left: 103.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this
      Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance
      with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&#160; The
      Company agrees not to take any position contrary to this Section 2(c).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Bid Price</u></font>&#8221; means, for any date, the price determined
      by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the
      Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
      Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open
      Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as
      determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>VWAP</u></font>&#8221; means, for any date, the price determined by
      the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on
      which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
      of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink
      Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as
      determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mechanics of Exercise</u></font>.</div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Delivery of Warrant Shares Upon Exercise</u></font>.&#160; The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the
        Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>DWAC</u></font>&#8221;) if the Company&#8217;s transfer agent
        is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the
        Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its
        designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to
        the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the
        Notice of Exercise (such date, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant Share Delivery Date</u></font>&#8221;).&#160;&#160; Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
        become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided&#160; that payment of the aggregate Exercise Price (other than in the case of a
        cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.&#160; If the Company fails for any reason to
        deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such
        exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day
        after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
        and exercisable. As used herein, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Standard Settlement Period</u></font>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading
        Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">ii.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Delivery of New Warrants Upon Exercise</u></font>.&#160; If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time
        of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this
        Warrant.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">iii.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u></u><font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rescission Rights</u></font>.&#160; If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder
        will have the right to rescind such exercise by delivering written notice to the Company at any time prior to the delivery of the Warrant Shares.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">iv.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u></font>.&#160; In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to
        transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in
        an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases for the Holder, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
        such exercise (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Buy-In</u></font>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage
        commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
        (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not
        honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&#160; For
        example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of
        $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and,
        upon request of the Company, evidence of the amount of such loss.&#160; Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
        performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">v.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Fractional Shares or Scrip</u></font>.&#160; No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160; As to any fraction of a share which the Holder would
        otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next
        whole share.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">vi.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Charges, Taxes and Expenses</u></font>.&#160; Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such
        Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
        when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
        incidental thereto.&#160; The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
        required for same-day electronic delivery of the Warrant Shares.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">vii.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Closing of Books</u></font>.&#160; The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Holder&#8217;s Exercise Limitations</u></font>.&#160; The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or
        otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder
        or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Attribution Parties</u></font>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For
        purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
        respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of
        its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other&#160; Common Stock Equivalents) subject to a limitation on
        conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
        ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
        in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith and the calculations required under this Section 2(e). To the extent that the limitation
        contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
        exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
        together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of
        such determination.&#160;&#160; In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&#160; For purposes of this
        Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission,
        as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or oral request of a
        Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be determined after giving
        effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.&#160; The &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Beneficial Ownership Limitation</u></font>&#8221; shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
        Stock issuable upon exercise of this Warrant.&#160; The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event
        exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue
        to apply.&#160; Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered to the Company.&#160; The provisions of this Section 2(e) shall be construed and implemented in a manner
        otherwise than in strict conformity with the terms of this <a name="z_Hlk97391303"></a>Section 2(e) to correct this Section 2(e) (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
        herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this Section 2(e) shall apply to a successor holder of this Warrant.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 3</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Certain Adjustments</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Stock Dividends and Splits</u></font>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock
        or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
        shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any
        shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
        such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
        aggregate Exercise Price of this Warrant shall remain unchanged.&#160; Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or
        distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Subsequent Rights Offerings</u></font>.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In addition to any adjustments pursuant to Section 3(a) above, if at any time the
          Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Co mmon Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the
          Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete
          exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such
          Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent
          that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
          ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the
          Holder exceeding the Beneficial Ownership Limitation).</font></font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Pro Rata Distributions</u></font>.&#160; During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to
        holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
        rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Distribution</u></font>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder
        shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
        to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record
        holders of shares of Common Stock are to be determined for the participation in such Distribution (<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in
        such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such
        time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Fundamental Transaction</u></font>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the
        Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
        of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their
        shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
        reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company<a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger
        or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other
        Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Fundamental

            Transaction</u></font>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such
        Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the
        surviving corporation, and any additional consideration (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Alternate Consideration</u></font>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of
        shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&#160; For purposes of any such exercise, the determination
        of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall
        apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&#160; If holders of Common Stock are given any choice as to the securities,
        cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&#160; The Company shall
        cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successor Entity</u></font>&#8221;) to assume in writing all of the obligations of
        the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without
        unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form
        and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
        Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the
        relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
        value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity
        shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity),
        and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named as the Company
        herein.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Calculations</u></font>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of
        Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notice to Holder</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Adjustment to Exercise Price</u></font>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice
        setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">ii.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notice to Allow Exercise by Holder</u></font>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring
        cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the
        approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of its assets,
        or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
        then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
        applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
        of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share
        exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
        upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
        be specified in such notice.&#160; To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
        the Commission pursuant to a Current Report on Form 8-K.&#160; The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may
        otherwise be expressly set forth herein.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 4</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transfer of Warrant</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transferability</u></font>.&#160; Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this
        Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
        assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160; Upon such surrender and, if
        required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to
        the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Notwithstanding anything herein to the contrary, the
          Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date
          on which the Holder delivers an assignment form to the Company assigning this Warrant in full.&#160; </font>The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a
        new Warrant issued.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>New Warrants</u></font>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and
        denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&#160; Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and
        deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with
        this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant Register</u></font>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant

            Register</u></font>&#8221;), in the name of the record Holder hereof from time to time.&#160; The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
        the Holder, and for all other purposes, absent actual notice to the contrary.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transfer Restrictions</u></font>. <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">If, at the </font><a name="z_DV_C75"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective
          registration</font><a name="z_DV_C76"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> statement under the Securities Act and </font><a name="z_DV_C78"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may
          require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 4.1 of the Purchase Agreement.</font></font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Representation by the Holder</u></font>.&#160; The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable
        upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered
        or exempted under the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 5</u>.</font>&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Miscellaneous</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u></font>.&#160; This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the
        exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.&#160; Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant
        to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Loss, Theft, Destruction or Mutilation of Warrant</u></font>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of
        this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond),
        and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock
        certificate.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Saturdays, Sundays, Holidays, etc</u></font>.&#160; If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action
        may be taken, or such right may be exercised on the next succeeding Trading Day.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Authorized Shares</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
      Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.&#160; The Company further covenants that its issuance of this Warrant shall constitute full authority to its
      officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160; The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
      be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&#160; The Company covenants that all Warrant Shares which may be issued upon the
      exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
      nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
      limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
      performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in
      this Warrant against impairment.&#160; Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par
      value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to
      obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Before taking any action that would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable
      or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Jurisdiction</u></font>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">f)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Restrictions</u></font>.&#160; The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions
        upon resale imposed by state and federal securities laws.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">g)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Nonwaiver and Expenses</u></font>.&#160; No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s
        rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the
        Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of the appellate proceedings, incurred by the Holder in
        collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notices</u></font>.&#160; Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase
        Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Limitation of Liability</u></font>.&#160; No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or
        privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">j)</font>&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Remedies</u></font>.&#160; The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&#160;
        The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific
        performance that a remedy at law would be adequate.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successors and Assigns</u></font>.&#160; Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and
        permitted assigns of the Company and the successors and permitted assigns of Holder.&#160; The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder
        of Warrant Shares.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Amendment</u></font>.&#160; This Warrant may be modified or amended, or the provisions hereof waived with the written consent of the Company <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and the Holder</font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">m)</font>&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severability</u></font>.&#160; Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be
        prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">n)</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Headings</u></font>.&#160; The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Execution</u></font>.&#160; This Warrant may be executed and delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; or similar format data file, in which case such signature shall create a valid and
        binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; or similar format signature page were an original thereof.</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">********************</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Signature Page Follows)</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</div>
    <div>&#160;</div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" align="" style="border-collapse: collapse; width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">

            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
              <td style="vertical-align: top;" colspan="2" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
              <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
              </td>
              <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 3%; vertical-align: top;"><br>
              </td>
              <td style="width: 47%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 3%; vertical-align: top;"><br>
              </td>
              <td style="width: 47%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title:</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTICE OF EXERCISE</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z19b8c2a958d44ceba4b4524ab1f64a07" class="DSPFListTable">

          <tr style="vertical-align: top;">
            <td style="vertical-align: top; width: 36pt;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">TO:</font></div>
            </td>
            <td style="align: left; vertical-align: top; width: auto;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">BROOKLYN IMMUNOTHERAPEUTICS, INC.</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">The undersigned hereby elects to purchase ________
        Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Payment shall take the form of (check applicable
        box):</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">[&#160; ] in lawful money of the United States; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
      exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Please issue said Warrant Shares in the name of the
        undersigned or in such other name as is specified below:</font></div>
    <div>&#160;</div>
    <div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 15%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
              <td style="width: 65%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 15%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
              <td style="width: 65%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%;">
                <div>&#160;</div>
              </td>
              <td style="width: 20%;">
                <div>&#160;</div>
              </td>
              <td style="width: 65%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
              <td style="width: 65%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%;">
                <div>&#160;</div>
              </td>
              <td style="width: 20%;">
                <div>&#160;</div>
              </td>
              <td style="width: 65%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 15%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
              <td style="width: 65%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">(4)&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Accredited Investor</u></font>.&#160; The undersigned is an &#8220;accredited investor&#8221;
      as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE OF HOLDER]</div>
    <br>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 20%; padding-bottom: 2px;">Name of Investing Entity:</td>
              <td style="width: 80%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 32%; padding-bottom: 2px;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Signature of Authorized Signatory of Investing Entity:</font> </td>
              <td style="width: 68%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 21%; padding-bottom: 2px;">Name of Authorized Signatory:</td>
              <td style="width: 79%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 20%; padding-bottom: 2px;">Title of Authorized Signatory: </td>
              <td style="width: 80%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 5%; padding-bottom: 2px;">Date:</td>
              <td style="width: 95%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div><br>
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXHIBIT B</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M89"></a>ASSIGNMENT FORM</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; text-indent: 18pt;"><a name="z_DV_M162"></a>&#160;(To assign the foregoing Warrant, execute this form and supply required information.&#160;
      Do not use this form to exercise the Warrant to purchase shares.)</div>
    <div style="text-indent: 18pt;">&#160;</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"><a name="z_DV_M163"></a>FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
            </td>
            <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 7%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 43%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(Please Print)</div>
            </td>
            <td style="width: 7%; vertical-align: top;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 43%; vertical-align: top;">&#160;</td>
            <td style="width: 7%; vertical-align: top;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" rowspan="1">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Address:</div>
            </td>
            <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; padding-bottom: 2px;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1"><br>
            </td>
            <td style="width: 43%; vertical-align: top;" rowspan="1">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(Please Print)</div>
            </td>
            <td style="width: 7%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 43%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;" rowspan="1">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Phone Number:</font></div>
            </td>
            <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top; padding-bottom: 2px;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 43%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Email Address:</font></div>
            </td>
            <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
            </td>
            <td style="width: 7%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 43%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Dated: _______________ __, ______</div>
            </td>
            <td style="width: 43%; vertical-align: top;">&#160;</td>
            <td style="width: 7%; vertical-align: top;" colspan="1">&#160;</td>
          </tr>

      </table>
    </div>
    <div>&#160;
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Holder&#8217;s Signature:</font></div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 43%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 7%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 30%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 5%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
            <td style="width: 43%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 7%; vertical-align: top;" colspan="1" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Holder&#8217;s Address:</font><br>
              </div>
            </td>
            <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
            <td style="width: 43%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 7%; vertical-align: top; padding-bottom: 2px;" colspan="1">&#160;</td>
          </tr>

      </table>
    </div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>brhc10034972_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div style="font-weight: bold; text-align: right;">Exhibit 10.3<br>
  </div>
  <div>
    <div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
    </div>
    <div style="text-align: left;">&#160;</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES
      COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE
      SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&#160; THIS SECURITY AND THE SECURITIES ISSUABLE
      UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">COMMON STOCK PURCHASE WARRANT</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z1acddef2aa8941aab2c39881aa50178c" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

        <tr>
          <td style="width: 70%;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Warrant Shares: 6,857,142</font></div>
          </td>
          <td style="width: 30%;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Issue Date:&#160; March 9, 2022</font></td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant</u></font>&#8221;) certifies that, for
      value received, Armistice Capital Master Fund Ltd. or its assigns (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Holder</u></font>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
      hereinafter set forth, at any time on or after six (6) months immediately following the date hereof (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Initial Exercise Date</u></font>&#8221;) and on or prior to 5:00 p.m. (New York City
      time) on September 9, 2027 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Termination Date</u></font>&#8221;) but not thereafter, to subscribe for and purchase from Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), up to 6,857,142 shares (as subject to adjustment hereunder, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant Shares</u></font>&#8221;) of
      Common Stock.&#160; The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 1</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Definitions</u></font>.&#160; Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchase Agreement</u></font>&#8221;), dated March 6, 2022, among the Company and the purchasers signatory thereto.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 2</u>.</font>&#160;&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise of Warrant</u></font>.&#160; Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the
        Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notice of Exercise</u></font>&#8221;).&#160; Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as
        aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank, unless the cashless exercise procedure
        specified in Section 2(c) below is specified in the applicable Notice of Exercise.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160; </font>No ink-original Notice of Exercise shall be required, nor shall any
        medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.&#160; &#160; Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until
        the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on
        which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number
        of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.&#160; The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The
        Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of such notice. <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">The Holder and any assignee, by acceptance of
          this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be
          less than the amount stated on the face hereof.</font></font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise Price</u></font>.&#160; The exercise price per share of Common Stock under this Warrant shall be <font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">$</font>1.91subject to
        adjustment as set forth herein (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exercise Price</u></font>&#8221;).</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Cashless Exercise</u></font>.&#160; If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant
        Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by
        dividing [(A-B) (X)] by (A), where:</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: -27pt; margin-left: 99pt; font-family: 'Times New Roman'; font-size: 10pt;">(A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such
      Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading
      hours&#8221; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
      of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Bloomberg</u></font>&#8221;) as of the time of the Holder&#8217;s execution of
      the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a
      Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
      2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: -36pt; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: -31.5pt; margin-left: 103.5pt; font-family: 'Times New Roman'; font-size: 10pt;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this
      Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance
      with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&#160; The
      Company agrees not to take any position contrary to this Section 2(c).</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Bid Price</u></font>&#8221; means, for any date, the price determined
      by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the
      Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
      Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open
      Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as
      determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>VWAP</u></font>&#8221; means, for any date, the price determined by
      the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on
      which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
      of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink
      Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as
      determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Mechanics of Exercise</u></font>.</div>
    </div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Delivery of Warrant Shares Upon Exercise</u></font>.&#160; The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the
        Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>DWAC</u></font>&#8221;) if the Company&#8217;s transfer agent
        is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the
        Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its
        designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to
        the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the
        Notice of Exercise (such date, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant Share Delivery Date</u></font>&#8221;)&#160;&#160; Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have
        become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided&#160; that payment of the aggregate Exercise Price (other than in the case of a
        cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.&#160; If the Company fails for any reason to
        deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such
        exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day
        after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding
        and exercisable. As used herein, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Standard Settlement Period</u></font>&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading
        Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">ii.</font>&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Delivery of New Warrants Upon Exercise</u></font>.&#160; If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time
        of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this
        Warrant.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">iii.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rescission Rights</u></font>.&#160; If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will
        have the right to rescind such exercise by delivering written notice to the Company at any time prior to the delivery of the Warrant Shares.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">iv.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</u></font>.&#160; In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to
        transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in
        an open market transaction or otherwise) or the Holder&#8217;s brokerage firm otherwise purchases for the Holder, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
        such exercise (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Buy-In</u></font>&#8221;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&#8217;s total purchase price (including brokerage
        commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
        (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not
        honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.&#160; For
        example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of
        $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and,
        upon request of the Company, evidence of the amount of such loss.&#160; Nothing herein shall limit a Holder&#8217;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
        performance and/or injunctive relief with respect to the Company&#8217;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">v.</font>&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Fractional Shares or Scrip</u></font>.&#160; No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&#160; As to any fraction of a share which the Holder would
        otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next
        whole share.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">vi.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Charges, Taxes and Expenses</u></font>.&#160; Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such
        Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
        when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax
        incidental thereto.&#160; The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions)
        required for same-day electronic delivery of the Warrant Shares.</font></div>
    <div style="margin-left: 108pt; text-indent: 36pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">vii.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Closing of Books</u></font>.&#160; The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Holder&#8217;s Exercise Limitations</u></font>.&#160; The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or
        otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder
        or any of the Holder&#8217;s Affiliates (such Persons, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Attribution Parties</u></font>&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For
        purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
        respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of
        its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other&#160; Common Stock Equivalents) subject to a limitation on
        conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial
        ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
        in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith and the calculations required under this Section 2(e).&#160; To the extent that the limitation
        contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
        exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
        together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of
        such determination.&#160;&#160; In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&#160; For purposes of this
        Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission,
        as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or oral request of a
        Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be determined after giving
        effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.&#160; The &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Beneficial Ownership Limitation</u></font>&#8221; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
        Stock issuable upon exercise of this Warrant.&#160; The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event
        exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue
        to apply.&#160; Any increase in the Beneficial Ownership Limitation will not be effective until the 61<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">st</sup> day after such notice is delivered to the Company.&#160; The provisions of this Section 2(e) shall be construed and implemented in a manner
        otherwise than in strict conformity with the terms of this Section 2(e) to correct this Section 2(e) (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
        changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this Section 2(e) shall apply to a successor holder of this Warrant.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 3</u>.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Certain Adjustments</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Stock Dividends and Splits</u></font>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock
        or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding
        shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any
        shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
        such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the
        aggregate Exercise Price of this Warrant shall remain unchanged.&#160; Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or
        distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Subsequent Rights Offerings</u></font>.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">In addition to any adjustments pursuant to Section 3(a) above, if at any time the
          Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares&#160; of Common Stock (the &#8220;<u>Purchase Rights</u>&#8221;), then the
          Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete
          exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such
          Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<u>provided</u>, <u>however</u>, that, to the extent
          that the Holder&#8217;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
          ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the
          Holder exceeding the Beneficial Ownership Limitation);</font></font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Pro Rata Distributions</u></font>.&#160; During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to
        holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
        rearrangement, scheme of arrangement or other similar transaction) (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Distribution</u></font>&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder
        shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
        to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record
        holders of shares of Common Stock are to be determined for the participation in such Distribution (<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that, to the extent that the Holder&#8217;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in
        such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such
        time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation);<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">.</font></font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Fundamental Transaction</u></font>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the
        Company with or into another Person (excluding a merger effected solely to change the Company&#8217;s name or domicile), (ii) the Company (and all of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license,
        assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or
        another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common
        Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
        effectively converted into or exchanged for other securities, cash or property, or (v) the Company<a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>, directly or indirectly, in one or more related transactions consummates a stock or share purchase
        agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50%
        of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase
        agreement or other business combination) (each a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Fundamental Transaction</u></font>&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to
        receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of
        this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Alternate Consideration</u></font>&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
        (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&#160; For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the
        amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative
        value of any different components of the Alternate Consideration.&#160; If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as
        to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as
        defined below) shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental
        Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such
        Fundamental Transaction; provided, however, that if the Fundamental Transaction is&#160; not within the Company&#8217;s control, including not approved by the Company&#8217;s Board of Directors, the Holder shall only be entitled to receive from the Company or any
        Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
        with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in
        connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received
        common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Black Scholes Value</u></font>&#8221; means
        the value of this Warrant based on the Black Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a
        risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the
        greater of 100% and the 100 day volatility obtained from the HVT function on Bloomberg (determined utilizing a 365-day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental
        Transaction, (C) the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such
        Fundamental Transaction and (ii) the highest VWAP during the period beginning on the Trading Day immediately preceding the announcement of the applicable Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if
        earlier) and ending on the Trading Day of the Holder&#8217;s request pursuant to this Section 3(d) and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination
        Date and (E) a zero cost of borrow.&#160; The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five (5) Trading Days of the Holder&#8217;s election and (ii)
        the date of consummation of the Fundamental Transaction.&#160; The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successor


            Entity</u></font>&#8221;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance
        reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the
        Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to
        the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise
        price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock
        and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in the form and substance to the Holder.
        Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction
        Documents referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents
        with the same effect as if such Successor Entity had been named as the Company herein.</font></div>
    <div>&#160;</div>
    <div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Calculations</u></font>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of
          Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></div>
    </div>
    <div> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">f)</font>&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notice to Holder</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Adjustment to Exercise Price</u></font>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice
        setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">ii.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notice to Allow Exercise by Holder</u></font>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring
        cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the
        approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of its assets,
        or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
        then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
        applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
        of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share
        exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
        upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
        be specified in such notice.&#160; To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
        the Commission pursuant to a Current Report on Form 8-K.&#160; The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice&#160; except as may
        otherwise be expressly set forth herein.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 4</u>.</font>&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transfer of Warrant</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transferability</u></font>.&#160; Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this
        Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
        assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&#160; Upon such surrender and, if
        required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to
        the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Notwithstanding anything herein to the contrary, the
          Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date
          on which the Holder delivers an assignment form to the Company assigning this Warrant in full.&#160; </font>The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a
        new Warrant issued.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>New Warrants</u></font>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and
        denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&#160; Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and
        deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with
        this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant Register</u></font>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Warrant


            Register</u></font>&#8221;), in the name of the record Holder hereof from time to time.&#160; The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to
        the Holder, and for all other purposes, absent actual notice to the contrary.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Transfer Restrictions</u></font>. <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">If, at the </font><a name="z_DV_C75"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective
          registration</font><a name="z_DV_C76"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> statement under the Securities Act and </font><a name="z_DV_C78"></a><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may
          require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 4.1 of the Purchase Agreement.</font></font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Representation by the Holder</u></font>.&#160; The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable
        upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered
        or exempted under the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Section 5</u>.</font>&#160;&#160;&#160; &#160; &#160; &#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Miscellaneous</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Rights as Stockholder Until Exercise; No Settlement in Cash</u></font>.&#160; This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the
        exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.&#160; Without limiting any rights of a Holder to receive Warrant Shares on a &#8220;cashless exercise&#8221; pursuant to Section 2(c) or to receive cash payments pursuant
        to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Loss, Theft, Destruction or Mutilation of Warrant</u></font>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of
        this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond),
        and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock
        certificate.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Saturdays, Sundays, Holidays, etc</u></font>.&#160; If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action
        may be taken or such right may be exercised on the next succeeding Trading Day.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d)</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Authorized Shares</u></font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common
      Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.&#160; The Company further covenants that its issuance of this Warrant shall constitute full authority to its
      officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.&#160; The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
      be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&#160; The Company covenants that all Warrant Shares which may be issued upon the
      exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and
      nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
      limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
      performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in
      this Warrant against impairment.&#160; Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par
      value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to
      obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable
      or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Jurisdiction</u></font>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Restrictions</u></font>.&#160; The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions
        upon resale imposed by state and federal securities laws.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Nonwaiver and Expenses</u></font>.&#160; No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s
        rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the
        Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in
        collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notices</u></font>.&#160; Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase
        Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">i)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Limitation of Liability</u></font>.&#160; No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or
        privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Remedies</u></font>.&#160; The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&#160;
        The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific
        performance that a remedy at law would be adequate.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successors and Assigns</u></font>.&#160; Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and
        permitted assigns of the Company and the successors and permitted assigns of Holder.&#160; The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder
        of Warrant Shares.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">l)</font>&#160;&#160; &#160; &#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Amendment</u></font>.&#160; This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company <font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">and the Holder</font>.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severability</u></font>.&#160; Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be
        prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">n)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Headings</u></font>.&#160; The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">o)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Execution</u></font>.&#160; <a name="z_Hlk97391315"></a>This Warrant may be executed and delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; or similar format data file, in which case such
        signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; or similar format signature page were an original thereof.</font></div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">********************</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Signature Page Follows)</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" align="" style="border-collapse: collapse; width: 100%; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;" id="zdc732716afc44a90923c7e67b7842d2c">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a name="z_Hlk97391341"></a>BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;"><br>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;"><br>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title:</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTICE OF EXERCISE</div>
    <div><br>
    </div>
    <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">TO:</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">BROOKLYN IMMUNOTHERAPEUTICS, INC.</font></div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(1)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">The undersigned hereby elects to purchase ________
        Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(2)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Payment shall take the form of (check applicable
        box):</font></div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">[&#160; ] in lawful money of the United States; or</div>
    <div>&#160;</div>
    <div style="text-align: justify; margin-left: 108pt; font-family: 'Times New Roman'; font-size: 10pt;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to
      exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</div>
    <div>&#160;</div>
    <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(3)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Please issue said Warrant Shares in the name of the
        undersigned or in such other name as is specified below:</font></div>
    <br>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <div>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 15%; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>
                <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div>&#160;</div>
                </td>
                <td style="width: 65%; padding-bottom: 2px;">
                  <div>&#160;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Warrant Shares shall be delivered to the following DWAC Account Number:</div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">
      <table cellspacing="0" cellpadding="0" border="0" id="ze0122edda62e4ef0b565f2de8afe72af" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 15%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
            <td style="width: 65%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;">
              <div>&#160;</div>
            </td>
            <td style="width: 65%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
            <td style="width: 65%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;">
              <div>&#160;</div>
            </td>
            <td style="width: 65%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 15%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
            <td style="width: 65%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">(4)&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Accredited Investor</u></font>.&#160; The undersigned is an &#8220;accredited investor&#8221;
      as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE OF HOLDER]</div>
    <br>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z68e23ff1007a4e38a259d02938516dff" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 20%; padding-bottom: 2px;">Name of Investing Entity:</td>
            <td style="width: 80%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 32%; padding-bottom: 2px;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Signature of Authorized Signatory of Investing Entity:</font> </td>
            <td style="width: 68%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 21%; padding-bottom: 2px;">Name of Authorized Signatory:</td>
            <td style="width: 79%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 20%; padding-bottom: 2px;">Title of Authorized Signatory: </td>
            <td style="width: 80%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 5%; padding-bottom: 2px;">Date:</td>
            <td style="width: 95%; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</font></div>
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXHIBIT B</div>
    <div><br>
    </div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M89"></a>ASSIGNMENT FORM</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br>
    </div>
    <div style="text-align: left; text-indent: 10.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><a name="z_DV_M162"></a>&#160;(To assign the foregoing Warrant, execute this form and supply required information.&#160;
      Do not use this form to exercise the Warrant to purchase shares.)</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 10.5pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_M163"></a>FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zc605e43ccd674528a1d303e7002fee8e">

        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
          </td>
          <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="1" style="width: 7%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 43%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(Please Print)</div>
          </td>
          <td colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
          <td style="width: 43%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Address:</div>
          </td>
          <td rowspan="1" style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 7%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 43%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">(Please Print)</div>
          </td>
          <td rowspan="1" colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 43%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><a name="z_DV_C128"></a><font style="font-size: 10pt; font-family: 'Times New Roman';">Phone Number:</font></div>
          </td>
          <td rowspan="1" style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 7%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 43%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Email Address:</font></div>
          </td>
          <td style="width: 43%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);"><br>
          </td>
          <td colspan="1" style="width: 7%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 43%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Dated: _______________ __, ______</div>
          </td>
          <td style="width: 43%; vertical-align: top;">&#160;</td>
          <td colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Holder&#8217;s Signature:</font></div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 43%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td colspan="1" style="width: 7%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 15%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 30%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 43%; vertical-align: top;">&#160;</td>
          <td rowspan="1" colspan="1" style="width: 7%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 15%; vertical-align: top; padding-bottom: 2px;">
            <div style="text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Holder&#8217;s Address:</font><br>
            </div>
          </td>
          <td style="width: 30%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 43%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td colspan="1" style="width: 7%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
  </div>
  <div><br>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>brhc10034972_ex10-4.htm
<DESCRIPTION>EXHIBIT 10.4
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 10.4</font><br>
      </div>
      <div style="text-align: right;"> <br>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: right; font-family: 'Times New Roman'; font-weight: bold;">EXECUTION VERSION</div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">REGISTRATION RIGHTS AGREEMENT</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Registration Rights Agreement (this &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Agreement</u></font>&#8221;) is made and
        entered into as of March 6, 2022, between Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), and each of the purchasers signatory hereto (each such
        purchaser, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchaser</u></font>&#8221; and, collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchasers</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Purchase Agreement</u></font>&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company and each Purchaser hereby agrees as follows:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.</font>&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Definitions</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Capitalized terms used and not otherwise defined herein that are
          defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.</font> As used in this Agreement, the following terms shall have the following meanings:</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 72pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Advice</u></font>&#8221; shall have the meaning set forth in Section 6(c).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Effectiveness Date</u></font>&#8221; means, with respect to the
        Initial Registration Statement required to be filed hereunder, the 30th calendar day following the Filing Date (or, in the event of a &#8220;full review&#8221; by the Commission, the 60th calendar day following the Filing Date) and with respect to any
        additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the 30th calendar day following the date on which an additional Registration Statement is required to be filed hereunder (or, in the event of a &#8220;full
        review&#8221; by the Commission, the 60th calendar day following the date such additional Registration Statement is required to be filed hereunder); <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to
        further review and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above, provided, further,
        if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 72pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Effectiveness Period</u></font>&#8221; shall have the meaning set forth in Section
        2(a).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Event</u></font>&#8221; shall have the meaning set forth in Section
        2(d).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Event Date</u></font>&#8221; shall have the meaning set forth in
        Section 2(d).</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Filing Date</u></font>&#8221; means, with respect to the Initial
        Registration Statement required hereunder, the 15th calendar day following the date on which the Company files its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and, with respect to any additional Registration Statements
        which may be required pursuant to Section 2(c) or Section 3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Holder</u></font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Holders</u></font>&#8221; means the holder or holders, as the case may be, from time to time of Registrable Securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnified Party</u></font>&#8221; shall have the meaning set forth
        in Section 5(c).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnifying Party</u></font>&#8221; shall have the meaning set
        forth in Section 5(c).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Initial Registration Statement</u></font>&#8221; means the initial
        Registration Statement filed pursuant to this Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Losses</u></font>&#8221; shall have the meaning set forth in Section
        5(a).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Plan of Distribution</u></font>&#8221; shall have the meaning set
        forth in Section 2(a).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Prospectus</u></font>&#8221; means the prospectus included in a
        Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission
        pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and
        supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registrable Securities</u></font>&#8221; means, as of any date of
        determination, (a) all Shares, (b) all Warrant Shares then issued and issuable upon exercise of the Warrants (assuming on such date the Warrants are exercised in full without regard to any exercise limitations therein), and (c) any securities
        issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided,</u></font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file
        another, Registration Statement hereunder with respect thereto) for so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such
        Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible for
        resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and&#160; the affected
        Holders (assuming that such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued or are issuable, were at no time held by any Affiliate of the Company), as
        reasonably determined by the Company, upon the advice of counsel to the Company.</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Statement</u></font>&#8221; means any registration
        statement required to be filed hereunder pursuant to Section 2(a) and any additional registration statements contemplated by Section 2(c) or Section 3(c) (in each case with respect to the Registrable Securities), including (in each case) the
        Prospectus, amendments and supplements to any such registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any
        such registration statement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rule 415</u></font>&#8221; means Rule 415 promulgated by the
        Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Rule 424</u></font>&#8221; means Rule 424 promulgated by the
        Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Selling Stockholder Questionnaire</u></font>&#8221; shall have the
        meaning set forth in Section 3(a).</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>SEC Guidance</u></font>&#8221; means (i) any publicly-available
        written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii) the Securities Act.<br>
        <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Shelf Registration</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">On or prior to each Filing Date,
          the Company shall prepare and file with the Commission a Registration Statement covering the resale of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a
          continuous basis pursuant to Rule 415.&#160; Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration
          shall be on Form S-1 or on another appropriate form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by at least 85% in interest of the Holders) the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Plan of Distribution</u></font>&#8221; substantially in the form attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Annex A</u></font> and the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Selling Stockholder</u></font>&#8221; section substantially in the form attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Annex B</u></font>; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that no Holder shall be required to be named as an &#8220;underwriter&#8221; without such Holder&#8217;s express prior
          written consent.&#160; Subject to the terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed under this Agreement (including, without limitation, under Section 3(c)) to be declared effective under the
          Securities Act as promptly as possible after the filing thereof, but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously effective under the Securities Act
          until the date that all Registrable Securities covered by such Registration Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the
          requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the
          Transfer Agent and the affected Holders&#160; (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Effectiveness Period</u></font>&#8221;).&#160; The Company shall telephonically request effectiveness of a Registration Statement as of 5:00
          p.m. (New York City time) on a Trading Day.&#160; The Company shall immediately notify the Holders via facsimile or by e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms
          effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement.&#160; The Company shall, by 9:30 a.m. (New York City time) on the Trading Day after the effective date of such Registration
          Statement, file a final Prospectus with the Commission as required by Rule 424.&#160; Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness or failure to file a final Prospectus as foresaid shall be deemed an
          Event under Section 2(d).</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"> Notwithstanding the registration
          obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration
          statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of
          Registrable Securities permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary offering, subject to the provisions of Section 2(e); with respect to
          filing on Form S-3 or other appropriate form, and subject to the provisions of Section 2(d) with respect to the payment of liquidated damages; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that prior to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration of all of the
          Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation 612.09.</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable
          Securities permitted to be registered on a particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with the Commission for the registration of all or a greater portion of
          Registrable Securities), unless otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:</font></div>
      <div><br>
      </div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z145c668085c847438720f9e2e24f7c38" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;">

              <tr style="vertical-align: top;">
                <td style="width: 54pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">a.</div>
                </td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc28602c1e56d4400beabddbfbc8d763c">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">b.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Second, the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the case that some Warrant Shares may be registered, to the
                Holders on a pro rata basis based on the total number of unregistered Warrant Shares held by such Holders); and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf3a9ab819b504d7e970c976eb5acb861">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">c.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Third, the Company shall reduce Registrable Securities represented by Shares (applied, in the case that some Shares may be registered, to the Holders on a pro
                rata basis based on the total number of unregistered Shares held by such Holders).</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">In the event of a cutback hereunder, the Company shall give each Holder at least five (5) Trading Days prior written notice
        along with the calculations as to such Holder&#8217;s allotment of Registrable Securities to be registered on such Registration Statement.&#160; In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company
        will use its best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form
        available to register for resale those Registrable Securities that were not registered for resale on the Initial Registration Statement, as amended.</div>
      <div style="text-align: justify; margin-left: 36pt;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">If: (i) the Initial Registration
          Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company shall
          be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities
          Act, within five Trading Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be &#8220;reviewed&#8221; or will not be subject to further review, or (iii) prior
          to the effective date of a Registration Statement, the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of such Registration Statement within ten (10) calendar days
          after the receipt of comments by or notice from the Commission that such amendment is required in order for such Registration Statement to be declared effective, or (iv), a Registration Statement registering for resale all of the Registrable
          Securities is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement, or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason&#160; to remain
          continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize the Prospectus therein to resell such Registrable Securities, for more than ten (10)
          consecutive calendar days or more than an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being referred to as an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Event</u></font>&#8221;, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose
          of clause (iii) the date which such ten (10) calendar day period is exceeded, and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period, as applicable, is exceeded being referred to as &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Event Date</u></font>&#8221;), then, in addition to any other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each
          such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product
          of 2.0<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>% multiplied by the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement.&#160; The parties agree that the maximum aggregate liquidated damages payable to a Holder under this Agreement shall be <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>12.0%
          of the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement.&#160; If the Company fails to pay any partial liquidated damages pursuant to this Section in full within seven (7) days after the date payable, the Company
          will pay interest thereon at a rate of <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#160;</sup>18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated damages are due until such
          amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">If Form S-3 is not available for
          the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the resale of the Registrable Securities on Form S-1 or another appropriate form and (ii) undertake to register the Registrable Securities on Form
          S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been
          declared effective by the Commission.</font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Notwithstanding anything to the
          contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate of a Holder as any Underwriter without the prior written consent of such Holder.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.</font>&#160;&#160;&#160;&#160;&#160; &#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Procedures</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In connection with the Company&#8217;s registration obligations hereunder, the Company shall:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Not less than five (5) Trading
          Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the filing of any related Prospectus or any amendment or supplement thereto (excluding any Annual Report on Form 10-K, Quarterly Report on Form
          10-Q and Current Report on Form 8-K, including any amendment thereto and any similar or successor reports) including any document that would be incorporated or deemed to be incorporated therein by reference), the Company shall (i) furnish to each
          Holder copies of all such documents proposed to be filed, which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders, and (ii) cause its officers, directors, counsel and
          independent registered public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning of the Securities Act. The
          Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is
          notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus
          or amendments or supplements thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Annex B</u></font> (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Selling Stockholder Questionnaire</u></font>&#8221;) on a date that is not less than two (2) Trading Days prior to the Filing Date or by the end of the fourth (4<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup>) Trading Day
          following the date on which such Holder receives draft materials in accordance with this Section.</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">(i) Prepare and file with the
          Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable
          Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the
          related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424, (iii) respond as promptly as reasonably
          possible to any comments received from the Commission with respect to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence from and to the
          Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply
          in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement during the applicable period in accordance
          (subject to the terms of this Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus as so supplemented.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">If during the Effectiveness
          Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to the
          applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such Registrable Securities.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">Notify the Holders of
          Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably
          possible (and in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus
          or any Prospectus supplement or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a &#8220;review&#8221; of such Registration Statement and whenever the Commission
          comments in writing on such Registration Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or any other federal or state
          governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order
          suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the
          suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage
          of time that makes the financial statements included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by
          reference untrue in any material respect or that requires any revisions to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain any
          untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vi) of the occurrence
          or existence of any pending corporate development with respect to the Company that the Company believes may be material and that, in the determination of the Company, makes it not in the best interest of the Company to allow continued
          availability of a Registration Statement or Prospectus; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>, that in no
          event shall any such notice contain any information which would constitute material, non-public information regarding the Company or any of its Subsidiaries.</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Use its best efforts to avoid
          the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable
          Securities for sale in any jurisdiction, at the earliest practicable moment.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Furnish to each Holder, without
          charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested
          by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly after the filing of such documents with the Commission, provided that any such item which is
          available on the EDGAR system (or successor thereto) need not be furnished in physical form.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Subject to the terms of this
          Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any
          amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"> Prior to any resale of
          Registrable Securities by a Holder, use its best efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification) of such Registrable
          Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom)
          effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement, provided that the
          Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to
          service of process in any such jurisdiction.</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">If requested by a Holder,
          cooperate with such Holder to facilitate the timely preparation and delivery of certificates (or evidence of book entry transfer) representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which
          certificates (or evidence of book entry transfer) shall be free, to the extent permitted by the Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as
          any such Holder may request.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Upon the
          occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances, taking into account the Company&#8217;s good faith assessment of any adverse consequences to the Company and its stockholders of the
          premature disclosure of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein
          by reference, and file any other required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus, as the case may be, will contain an untrue statement of a material fact or omit to state a material fact
          required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160; If the
            Company notifies the Holders in accordance with clauses </font>(iii) through (vi)<font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> of Section 3(d) above to suspend the use of any Prospectus until the
            requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus.&#160; The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.&#160; The
            Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d),
            for a period not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.</font></font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">Otherwise use commercially
          reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any
          supplement or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at any time during the Effectiveness Period, the Company does not satisfy the conditions specified in
          Rule 172 and, as a result thereof, the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the
          Registrable Securities hereunder.</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';">If then eligible to use Form
          S-3, the Company shall use its commercially reasonable efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the registration of the resale of Registrable Securities.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';">The Company may require each
          selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control
          over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable Securities solely because any Holder fails to furnish such information within three (3) Trading
          Days of the Company&#8217;s request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such
          information is delivered to the Company.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Expenses</u></font>. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant
          to a Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and expenses of the Company&#8217;s counsel and
          independent registered public accountants) (A) with respect to filings made with the Commission, (B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C) in compliance
          with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the
          Registrable Securities), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the
          Company, (v) Securities Act liability insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this
          Agreement.&#160; In addition, the Company shall be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses
          of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
          hereunder.&#160; In no event shall the Company be responsible for any underwriting discounts or broker or similar commissions or fees of any Holder or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of
          the Holders.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnification</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnification by the Company</u></font>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, members, partners, agents,
          brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of Common Stock) investment advisors and employees (and any other Persons with a functionally
          equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the
          Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title)
          of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable and documented attorneys&#8217; fees) and expenses
          (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Losses</u></font>&#8221;), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement,
          any Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of <a name="z_Hlk97386107"></a>a material fact required to be
          stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation or alleged violation by the Company of
          the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such untrue
          statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder&#8217;s proposed
          method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that
          the Holder has approved Annex A hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(iv), the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after
          the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section 6(c).&#160; The Company shall
          notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and
          effect regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnification by Holders</u></font>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the
          Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against
          all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any
          preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light
          of the circumstances under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing by such Holder to the Company expressly for
          inclusion in such Registration Statement or such Prospectus or (ii) to the extent, but only to the extent, that such information relates to such Holder&#8217;s information provided in the Selling Stockholder Questionnaire or the proposed method of
          distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder explresly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this purpose), such
          Prospectus or in any amendment or supplement thereto.&#160; In no event shall the liability of a selling Holder be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating
          to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission) received by such Holder upon the sale of the Registrable Securities included in the Registration
          Statement giving rise to such indemnification obligation.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Conduct of Indemnification Proceedings</u></font>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnified Party</u></font>&#8221;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Indemnifying Party</u></font>&#8221;) in
          writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with
          defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be
          finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense
        thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless:&#160; (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed
        promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such
        Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying
        Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense
        thereof and the reasonable and documented fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party).&#160; The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected
        without its written consent, which consent shall not be unreasonably withheld or delayed.&#160; No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which
        any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</div>
      <div><br>
      </div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and
        expenses, to the extent incurred, in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section 5) shall be paid to the Indemnified Party, as incurred, within ten (10) Trading Days of written
        notice thereof to the Indemnifying Party, provided that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally
        determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Contribution</u></font>. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying
          Party shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or
          omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in
          question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and
          the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission.&#160; The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the
          limitations set forth in this Agreement, any reasonable and documented attorneys&#8217; or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if
          the indemnification provided for in this Section 5 was available to such party in accordance with its terms.</font></div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by
        pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph.&#160; In no event shall the contribution obligation of a Holder of Registrable
        Securities be greater in amount than the dollar amount of the proceeds (net of all expenses paid by usch Holder in connection with any claim relating to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by
        reason of such untrue or alleged untrue statement or omission or alleged omission) received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The indemnity and contribution agreements contained in this Section 5 are in addition to any liability that the Indemnifying
        Parties may have to the Indemnified Parties.</div>
      <div style="text-align: justify; text-indent: 36pt; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.</font>&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Miscellaneous</u></font>.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Remedies</u></font>.&#160; In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise
          all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement.&#160; Each of the Company and each Holder agrees that monetary damages would not provide
          adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not
          assert or shall waive the defense that a remedy at law would be adequate.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Piggyback on Registrations; Prohibition on Filing Other Registration Statements</u></font>.&#160; Neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities
          of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration Statement that is
          declared effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing (i) amendments to registration statements filed prior to the date of this Agreement so long as no new securities are registered on
          any such existing registration statements and (ii) a registration statement on Form S-8 pursuant to any benefits plans or arrangements existing on the date of this Agreement.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Discontinued Disposition</u></font>.&#160; By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(d)(iii)
          through (vi), such Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Advice</u></font>&#8221;)
          by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed.&#160; The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable.&#160;
          The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d).</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Amendments and Waivers</u></font>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may
          not be given, unless the same shall be in writing and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes any Registrable Securities issuable upon
          exercise or conversion of any Security), provided that, if any amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group of Holders)
          shall be required.&#160; If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for
          each Holder shall be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to
          depart from the provisions hereof with respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such Holder or Holders
          of all of the Registrable Securities to which such waiver or consent relates; <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>however</u></font>,
          that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the first&#160; sentence of this Section 6(d). No consideration shall be offered or paid to any Person to amend or consent
          to a waiver or modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this Agreement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Notices</u></font>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth in the Purchase Agreement.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Successors and Assigns</u></font>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. The Company may not
          assign (except by merger) its rights or obligations hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities.&#160; Each Holder may assign their respective rights hereunder in the manner and to
          the Persons as permitted under Section 5.7 of the Purchase Agreement, provided, for the avoidance of doubt, no assignment by any party hereto of such party&#8217;s rights, duties and obligations hereunder shall be binding upon or obligate Company
          unless and until the Company shall have received (i) written notice of such assignment as provided in this Section 6(f) and (ii) the written agreement of the assignee, in the form attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Exhibit A</u></font>, to be bound by the terms and provisions of this Agreement. Any transfer or assignment made other than as provided in this Section 6(f) shall be null and void.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>No Inconsistent Agreements</u></font>. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of its Subsidiaries, on or after the date of this Agreement, enter into any
          agreement with respect to its securities, that would have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof.&#160; Except as set forth on <font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Schedule 6(i)</u></font>, neither the Company nor any of its Subsidiaries has previously entered into any agreement granting any registration rights with respect to any of its securities to any Person that
          have not been satisfied in full.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Execution and Counterparts</u></font>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have
          been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart.&#160; In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; format
          data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Governing Law</u></font>.&#160; All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the Purchase Agreement.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(j)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Cumulative Remedies</u></font>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(k)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Severability</u></font>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions,
          covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative
          means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
          terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</font></div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"> <br>
        </font></div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(l)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Headings</u></font>. The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or affect any of the provisions hereof.</font></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(m)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-size: 10pt; font-family: 'Times New Roman';"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Independent Nature of Holders&#8217; Obligations and Rights</u></font>. The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be responsible in any
          way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall be deemed to
          constitute the Holders as a partnership, an association, a joint venture or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect to such obligations or
          the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or
          transactions. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional party in any
          proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the convenience of the
          Company and not because it was required or requested to do so by any Holder.&#160; It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and the
          Holders collectively and not between and among Holders.</font></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">********************</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">(Signature Pages Follow)</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-size: 10pt;">
        <div style="text-align: right; font-family: 'Times New Roman'; font-weight: bold;">EXECUTION VERSION</div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">IN WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbf2b06cf28b342c4b3d1a1873e751fb8">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BROOKLYN IMMUNOTHERAPEUTICS, INC.</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="2" style="vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 3%; vertical-align: top; padding-bottom: 2px;">By:</td>
            <td rowspan="1" style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Howard J. Federoff</font></div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 3%; vertical-align: top;"><br>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name: Howard J. Federoff</div>
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title: President and Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div style="text-align: left;"><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE PAGE OF HOLDERS FOLLOWS]</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE PAGE OF HOLDERS TO RRA]</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name of Holder: Armistice Capital Master Fund Ltd.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd6600948a1154bc588ea712029355bd5">

          <tr>
            <td style="width: 33%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">Signature of Authorized Signatory of Holder</font>:</div>
            </td>
            <td style="width: 15%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-left: 9pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">/s/ Steven Boyd</font></div>
            </td>
            <td colspan="1" style="width: 52%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name of Authorized Signatory: Steven Boyd</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title of Authorized Signatory: CIO of Armistice Capital, LLC, the Investment Manager</div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[SIGNATURE PAGES CONTINUE]</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXHIBIT A</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">REGISTRATION RIGHTS AGREEMENT JOINDER</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned is executing and delivering this Registration Rights Agreement Joinder (this &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Joinder</u></font>&#8221;)
        pursuant to the Registration Rights Agreement dated as of March 6, 2022 (as the same may hereafter be amended, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Rights and Lock-Up Agreement</u></font>&#8221;), among
        Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation, and the other persons named as parties therein.</div>
      <div>&#160;</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">By executing and delivering this Joinder, the undersigned hereby agrees to become a party to, to be bound by, and to comply with the provisions of the Registration
        Rights Agreement as a Holder of Registrable Securities in the same manner as if the undersigned were an original signatory to the Registration Rights Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Accordingly, the undersigned has executed and delivered this Joinder as of the ____ day of &#160; &#160; &#160;&#160; , 20</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbafa49523a2447268009ca1b79849169">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">HOLDER:</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">[&#9679;]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="vertical-align: middle; width: 47%;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Its:</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Address for Notices:</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">[&#9679;]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">[&#9679;]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">[&#9679;]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">[&#9679;]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Agreed and Accepted as of</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
            <td colspan="2" style="vertical-align: middle;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td colspan="2" style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">[&#9679;]</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="vertical-align: middle; width: 47%;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;">
              <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Its:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Annex A</u></div>
      <div><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><u>Plan of Distribution</u></div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Each Selling Stockholder (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Selling Stockholders</u></font>&#8221;) of the securities
        and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal Trading Market or any other stock exchange, market or trading facility on which the
        securities are traded or in private transactions.&#160; These sales may be at fixed or negotiated prices.&#160; A Selling Stockholder may use any one or more of the following methods when selling securities:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2630a2ad25f3492d8c2563f854097e5e">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">ordinary brokerage transactions and transactions in which the broker&#8209;dealer solicits purchasers;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5ed4f1daad046e1bef6806d1790caa3">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">block trades in which the broker&#8209;dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9382885384f542f5809795c7ecb79811">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">purchases by a broker&#8209;dealer as principal and resale by the broker&#8209;dealer for its account;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8be6db13691e42148d6d7e06a9d10e44">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">an exchange distribution in accordance with the rules of the applicable exchange;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfef63ad5dfb446028003c750d16cfb79">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">privately negotiated transactions;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z81972949803441d6bf4f76eab77efb7e">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">settlement of short sales;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zdf36de46cf9c468cb19143fa2aa69b93">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">in transactions through broker&#8209;dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z5019ce8557d84cd4a1bdcf501499d332">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6e31d76a187349828108c3c4176dfe6e">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">a combination of any such methods of sale; or</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z94a18c7484b74985b930dcf728f4f94f">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: left;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">any other method permitted pursuant to applicable law.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as
        amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Securities Act</u></font>&#8221;), if available, rather than under this prospectus. The Selling Stockholders will act independently of us in making decisions with respect to
        the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the over-the-counter market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in
        negotiated transactions.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In addition, a Selling Stockholder that is an entity may elect to make an in-kind distribution of securities to its members, partners or
        stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely tradeable securities pursuant to the
        distribution through a registration statement. To the extent a distributee is an affiliate of ours (or to the extent otherwise required by law), we may file a prospectus supplement in order to permit the distributees to use the prospectus to resell
        the securities acquired in the distribution. The Selling Stockholders also may transfer the securities in other circumstances, in which case the transferees, pledgees or other successors-in-interest will be the selling beneficial owners for
        purposes of this prospectus. Upon being notified by the Selling Stockholders that a donee, pledgee, transferee, other successor-in-interest intends to sell our securities, we will, to the extent required, promptly file a supplement to this
        prospectus to name specifically such person as a Selling Stockholder.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Broker&#8209;dealers engaged by the Selling Stockholders may arrange for other brokers&#8209;dealers to participate in sales.&#160; Broker&#8209;dealers may receive
        commissions or discounts from the Selling Stockholders (or, if any broker&#8209;dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the
        case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
        or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume.&#160; The Selling Stockholders may also sell securities short and deliver these securities to close out their
        short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities.&#160; The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one
        or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this
        prospectus (as supplemented or amended to reflect such transaction).</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the
        meaning of the Securities Act in connection with such sales.&#160; In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or
        discounts under the Securities Act.&#160; Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities.&#160; The Company has
        agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
        without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144 without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any
        other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect.&#160; The resale securities will be sold only through registered or licensed
        brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an
        exemption from the registration or qualification requirement is available and is complied with.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not, subject to
        certain exceptions, simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution.&#160; In addition, the Selling
        Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholders or any
        other person.&#160; We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with
        Rule 172 under the Securities Act).</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SELLING STOCKHOLDERS</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The common stock being offered by the Selling Stockholders are those previously issued to the Selling Stockholders, and those issuable to the
        Selling Stockholders, upon exercise of the warrants.&#160; For additional information regarding the issuances of those shares of common stock and warrants, see &#8220;Private Placement of Shares of Common Stock and Warrants&#8221; above.&#160; We are registering the
        shares of common stock in order to permit the Selling Stockholders to offer the shares for resale from time to time.&#160; Except for the ownership of the shares of common stock and the warrants, the Selling Stockholders have not had any material
        relationship with us within the past three years.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of common stock by each of the
        Selling Stockholders.&#160; The second column lists the number of shares of common stock beneficially owned by each Selling Stockholder, based on its ownership of the shares of common stock and warrants, as of ________, 2022, assuming exercise of the
        warrants held by the Selling Stockholders on that date, without regard to any limitations on exercises.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The third column lists the shares of common stock being offered by this prospectus by the Selling Stockholders.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">In accordance with the terms of a registration rights agreement with the Selling Stockholders, this prospectus generally covers the resale of the
        sum of (i) the number of shares of common stock issued to the Selling Stockholders in the &#8220;Private Placement of Shares of Common Stock and Warrants&#8221; described above and (ii) the maximum number of shares of common stock issuable upon exercise of the
        related warrants, determined as if the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, each as of the trading day immediately preceding
        the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without regard to any limitations on the exercise of the warrants.<font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">&#160; </font>The fourth column assumes the sale of all of the shares offered by the Selling Stockholders pursuant to this prospectus.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Under the terms of the warrants, a Selling Stockholders may not exercise the warrants to the extent such exercise would cause such Selling
        Stockholders, together with its affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as applicable, of our then outstanding common stock following such exercise, excluding for
        purposes of such determination shares of common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second and fourth columns do not reflect this limitation.&#160; The Selling Stockholders may sell
        all, some or none of their shares in this offering.&#160; See &#8220;Plan of Distribution.&#8221;</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6fcbb94c11834ce19710b43567a205d6">

          <tr>
            <td style="width: 32.75%; vertical-align: bottom; text-align: center;">
              <div><u>&#160;</u></div>
              <div><u>&#160;</u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Name of Selling Stockholder</u></div>
            </td>
            <td style="width: 22.82%; vertical-align: bottom; text-align: center;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Number of shares of</u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Common Stock Owned</u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Prior to Offering</u></div>
            </td>
            <td style="width: 23.48%; vertical-align: bottom; text-align: center;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Maximum Number of<br>
                </u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>shares of Common Stock to</u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>be Sold Pursuant to this</u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Prospectus</u></div>
            </td>
            <td style="width: 20.96%; vertical-align: bottom; text-align: center;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Number of shares of</u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>Common Stock Owned</u></div>
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>After Offering</u></div>
            </td>
          </tr>

      </table>
      <div style="text-align: right;"><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">EXECUTION VERSION</div>
        <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
        </div>
      </div>
      <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Annex C</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">COMPANY</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Selling Stockholder Notice and Questionnaire</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned beneficial owner of common stock (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registrable Securities</u></font>&#8221;)
        of Brooklyn ImmunoTherapeutics, Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Company</u></font>&#8221;), understands that the Company has filed or intends to file with the Securities and Exchange
        Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Commission</u></font>&#8221;) a registration statement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Statement</u></font>&#8221;) for the
        registration and resale under Rule 415 of the Securities Act of 1933, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Securities Act</u></font>&#8221;), of the Registrable Securities, in accordance with the terms of the
        Registration Rights Agreement (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Registration Rights Agreement</u></font>&#8221;) to which this document is annexed.&#160; A copy of the Registration Rights Agreement is available from the
        Company upon request at the address set forth below.&#160; All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Certain legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus.&#160; Accordingly,
        Holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling stockholder in the Registration Statement and the related
        prospectus.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTICE</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned beneficial owner (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Selling Stockholder</u></font>&#8221;) of
        Registrable Securities hereby elects to include the Registrable Securities owned by it in the Registration Statement.</div>
      <div>&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%-->
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:</div>
      <div>&#160;</div>
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">QUESTIONNAIRE</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z8aef9c5004f74734a3d3bf148e1b07bb" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td colspan="1" rowspan="1" style="width: 5%; vertical-align: top; font-weight: bold;">1.<br>
            </td>
            <td colspan="2" rowspan="1" style="width: 5%; vertical-align: top;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Name.</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" rowspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" rowspan="1" style="width: 5%; vertical-align: top;">(a)</td>
            <td rowspan="1" style="width: 100%; vertical-align: top;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Full Legal Name of Selling Stockholder</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 100%; vertical-align: top;"><br>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top;">(b)</td>
            <td rowspan="1" style="width: 100%; vertical-align: top;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" style="width: 100%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top;">(c)</td>
            <td rowspan="1" style="width: 100%; vertical-align: top;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt;">Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by
                this Questionnaire):</div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td rowspan="1" style="width: 100%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2.&#160; Address for Notices to Selling Stockholder:</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6485b9ebbb684be0bc05eef386152278">

          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 8%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Telephone:</div>
            </td>
            <td style="width: 92%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><br>
              </div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 4%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Fax:</div>
            </td>
            <td style="width: 96%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><br>
              </div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 11%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Contact Person:</div>
            </td>
            <td style="width: 89%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><br>
              </div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">3.&#160; Broker-Dealer Status:</div>
      <div>&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" id="z13930459ce8f4e57934408637dd07b59" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">(a)</td>
              <td style="width: 100%;">
                <div>
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">Are you a broker-dealer?</div>
                </div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div>
          <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Yes&#160; &#9744;&#160;&#160;&#160;&#160;&#160; No&#160; &#9744;</font></div>
        </div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">(b)</td>
              <td style="width: 100%;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">If &#8220;yes&#8221; to Section 3(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?</div>
              </td>
            </tr>

        </table>
        <div>
          <div><br>
          </div>
          <div>
            <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Yes&#160; &#9744;&#160;&#160;&#160;&#160;&#160; No&#160; &#9744;</font></div>
          </div>
        </div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">Note:</td>
              <td style="width: 100%;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">If &#8220;no&#8221; to Section 3(b), the Commission&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</div>
              </td>
            </tr>

        </table>
      </div>
      <div> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 5%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 5%;">(c)</td>
                <td style="width: 100%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">Are you an affiliate of a broker-dealer?</div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
        <div>&#160;</div>
      </div>
      <div>
        <div>
          <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Yes&#160; &#9744;&#160;&#160;&#160;&#160;&#160; No&#160; &#9744;</font></div>
        </div>
      </div>
      <br>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; text-align: left; vertical-align: top;">(d)</td>
              <td style="width: 100%;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase
                      of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?</div>
                  </div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div>&#160;</div>
      <div>
        <div>
          <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Yes&#160; &#9744;&#160;&#160;&#160;&#160;&#160; No&#160; &#9744;</font></div>
        </div>
      </div>
      <div>&#160;</div>
      <div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 5%;"><br>
                  </td>
                  <td style="width: 5%;">Note:</td>
                  <td style="width: 100%;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                        <div style="font-family: 'Times New Roman'; font-size: 10pt;">If &#8220;no&#8221; to Section 3(d), the Commission&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</div>
                      </div>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div>&#160;</div>
      <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4.&#160; Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.</div>
      <div>&#160;</div>
      <div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the
        Company other than the securities issuable pursuant to the Purchase Agreement.</div>
      <div> <br>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 5%;">
                  <div>&#160;</div>
                </td>
                <td style="width: 5%; text-align: left; vertical-align: top;">(a)</td>
                <td style="width: 100%;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                        <div style="font-family: 'Times New Roman'; font-size: 10pt;">Type and Amount of other securities beneficially owned by the Selling Stockholder:</div>
                      </div>
                    </div>
                  </div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z9b80e583ce4c4f669787099515022679" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 10%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 90%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 10%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 90%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: left; text-indent: -72pt; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5.&#160; Relationships with the Company:</div>
      <div>&#160;
        <div>
          <div>
            <div>
              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

                  <tr>
                    <td style="width: 10%;"><br>
                    </td>
                    <td style="width: 90%;">
                      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                        <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                          <div style="font-family: 'Times New Roman'; font-size: 10pt;">
                            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders
                              (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.</div>
                          </div>
                        </div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 10%;">&#160;</td>
                    <td rowspan="1" style="width: 90%;">&#160;</td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 10%;">&#160;</td>
                    <td rowspan="1" style="width: 90%;">
                      <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">State any exceptions here:</div>
                    </td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 10%; padding-bottom: 2px;">&#160;</td>
                    <td rowspan="1" style="width: 90%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                  </tr>
                  <tr>
                    <td rowspan="1" style="width: 10%; padding-bottom: 2px;">&#160;</td>
                    <td rowspan="1" style="width: 90%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                  </tr>

              </table>
            </div>
          </div>
        </div>
        <div>&#160;</div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur
        subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or
        its affiliates.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the
        inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.&#160; The undersigned understands that such information will be relied upon by the Company in connection with the
        preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.</div>
      <div>&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person
        or by its duly authorized agent.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="zdaa24db8a29b47898fdb50adea398c64">

          <tr>
            <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Date:</div>
            </td>
            <td style="width: 40%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            <td colspan="1" style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 14%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Beneficial Owner:</div>
            </td>
            <td style="width: 36%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 40%; vertical-align: top;">&#160;</td>
            <td colspan="1" style="width: 5%; vertical-align: top;">&#160;</td>
            <td style="width: 14%; vertical-align: top;">&#160;</td>
            <td style="width: 36%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
            <td style="width: 3%; vertical-align: top; padding-bottom: 2px;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Name:</div>
            </td>
          </tr>
          <tr>
            <td colspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 47%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Title:</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PLEASE FAX A COPY (OR EMAIL A .PDF COPY) OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:</div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div style="text-align: center;"><font id="DSPFPageNumber" style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>brhc10034972_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 8.1.1.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div><br>
  </div>
  <div>
    <div style="background-color: #FEFEFE;">
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement</div>
    </div>
    <div style="background-color: #FEFEFE;">
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">New York, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (&#8220;Brooklyn&#8221;), a biopharmaceutical company focused on
        exploring the role that cytokine, and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that it has closed its previously announced private placement with a leading
        healthcare investor. The gross proceeds to Brooklyn from the private placement, before deducting the placement agent&#8217;s fees and other estimated fees and expenses related to the offering payable by Brooklyn, were approximately $12 million. Brooklyn
        intends to use the net proceeds from the private placement for general working capital purposes.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the terms of the securities purchase agreement, Brooklyn issued 6,857,142 units at a price of $1.75 per unit to the investor. Each unit
        consisted of one share of common stock (or one pre-funded warrant in lieu thereof), and a five-and-a-half-year warrant to purchase one share of common stock at an exercise price of $1.91 per share.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cantor Fitzgerald &amp; Co. acted as placement agent for the private placement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The securities were offered and sold in a private placement and were not registered under the Securities Act of 1933, as amended, and may not be offered
        or sold in the United States absent registration or an applicable exemption from registration requirements. Brooklyn has agreed to file a resale registration statement with the Securities and Exchange Commission (the &#8220;SEC&#8221;), for purposes of
        registering the resale of the shares of common stock issued or issuable in connection with the offering.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor may there be any sale of any securities in any state
        or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">About Brooklyn ImmunoTherapeutics</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and
      monogenic diseases.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brooklyn&#8217;s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck
      cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brooklyn has multiple next-generation cell and gene editing therapies in preclinical development for various indications including acute respiratory
      distress syndrome, solid tumor indications, as well as <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">in vivo</font> gene-editing therapies for rare genetic diseases. For more information about
      Brooklyn and its clinical programs, please visit <u><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">www.BrooklynITx.com</font></u>.</div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after:always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Forward-Looking Statements</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking
      statements are statements that are not historical facts. Words such as &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential&#8221; or the negatives of these terms or variations of
      them or similar expressions are intended to identify forward-looking statements. These statements in this press release include, but are not limited to, statements regarding <font style="background-color: #FEFEFE; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the use of proceeds from the private placement.</font> These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management, and are
      subject to a number of risks and uncertainties. Factors that could cause actual results to differ materially from current expectations include, without limitation: our dependence on the success of our internal development programs; whether or not our
      product pipeline candidates successfully complete clinical trials, receive regulatory approval and can be successfully commercialized; our ability to fund, enroll and complete our clinical trials; whether we generate the expected benefits of any
      acquisitions or joint ventures; our ability to maintain orphan drug exclusivity for IRX-2; undesirable side effects of our current or future product candidates; the impact of the current pandemic of the novel coronavirus (COVID-19) and its impacts on
      our business, including our ability to enroll persons in our clinical trials; our limited operating history; and the cautionary statements and risk factors described in our Current Report on Form 8-K filed with the SEC on May 11, 2021, our Quarterly
      Report on Form 10-Q for the quarter ended September 30, 2021 and our other filings filed from time to time with the SEC. We do not assume any obligation to update any forward-looking statement, except as required by law.</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investor Relations Contact:</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>Solebury Trout<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>917-936-8430<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      investors@brooklynitx.com</font></div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> <br>
      </font></div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Media Contact:</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>Michael V. Morabito, Ph.D.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Solebury Trout</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">917-936-8430</div>
    <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 10pt;"><u>btx@soleburytrout.com</u></div>
  </div>
  <div><br>
  </div>
  <div><br>
  </div>
  <div>
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>btx-20220306.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://brooklynitx.com/20220306" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:btx="http://brooklynitx.com/20220306" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20220306_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="btx-20220306_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>btx-20220306_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>btx-20220306_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 8.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://brooklynitx.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="btx-20220306.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://brooklynitx.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140540779373240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 06, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  06,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Brooklyn ImmunoTherapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-11460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-1103425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">140 58th Street, Building A<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brooklyn<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">582-1199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000748592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.005 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BTX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>brhc10034972_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="btx-20220306.xsd" xlink:type="simple"/>
    <context id="c20220306to20220306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000748592</identifier>
        </entity>
        <period>
            <startDate>2022-03-06</startDate>
            <endDate>2022-03-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20220306to20220306"
      id="Fact_6ca1d790ca5448a595c0e90a908da3ea">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20220306to20220306"
      id="Fact_80970cb4eb9a479f8a3e1058b8bb3d45">0000748592</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20220306to20220306"
      id="Fact_de9b323e470c4d9ba6a5cd4240e0eb56">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20220306to20220306"
      id="Fact_ceec8bd6e60845cf87a5fecdeb4f69d8">2022-03-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20220306to20220306"
      id="Fact_dae207efe8374c9a813483d7b1325129">Brooklyn ImmunoTherapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20220306to20220306"
      id="Fact_2a716859b9ba47409222e1ebdb391a9b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20220306to20220306"
      id="Fact_2c7595ddd244428797f4c17844692594">001-11460</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20220306to20220306"
      id="Fact_c4ec5567f855490b9f8ca55115368560">31-1103425</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20220306to20220306"
      id="Fact_871da459a47046d78969461a08dbff8f">140 58th Street, Building A</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="c20220306to20220306"
      id="Fact_95d39381160440fa9a231b2d495ba5f8">Suite 2100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="c20220306to20220306"
      id="Fact_7735424b6d844ac4bbd414f70d15e5d7">Brooklyn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20220306to20220306"
      id="Fact_3edc5df86a254dac8f6879143da2dc39">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20220306to20220306"
      id="Fact_27b97b81eaa949509e4877eaf7f3655c">11220</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20220306to20220306"
      id="Fact_7376f54987ad4649b1d18e8385c14f4b">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20220306to20220306"
      id="Fact_c65f65a7b8544417b721685870492201">582-1199</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20220306to20220306"
      id="Fact_8edcaa177fea4e48a056519d518f7b24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20220306to20220306"
      id="Fact_f83c1bddc44640738ab8224f169965db">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20220306to20220306"
      id="Fact_5b24e5a854134768a158b073539ceef0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20220306to20220306"
      id="Fact_d20291bcf2b0451d89fa143ee1c331d2">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20220306to20220306"
      id="Fact_ed3423f0a8b44415b9c226aed323ad93">Common Stock, par value $0.005 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20220306to20220306"
      id="Fact_8f4119001c4a483abd61dd38535bae00">BTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20220306to20220306"
      id="Fact_e2b5d0117fe34d7f8fd07ceab627d657">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20220306to20220306"
      id="Fact_2342a3cbf2034ff7a60e5181d9083891">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ J8)I5&60>9(9 0  SP,  !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !
M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB
M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G
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M+GAM;%!+ 0(4 Q0    ( *F":50R4O23[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *F":5297)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ J8)I5)F6!VI:!   _Q   !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *F":52?H!OPL0(
M .(,   -              "  9T,  !X;"]S='EL97,N>&UL4$L! A0#%
M  @ J8)I5)>*NQS     $P(   L              ( !>0\  %]R96QS+RYR
M96QS4$L! A0#%     @ J8)I5!PX9>H_ 0  / (   \              ( !
M8A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *F":50D'INBK0   /@!
M   :              "  <X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<U!+ 0(4 Q0    ( *F":51ED'F2&0$  ,\#   3              "  ;,2
K  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /T3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>118</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="brhc10034972_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://brooklynitx.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="brhc10034972_8k.htm">brhc10034972_8k.htm</File>
    <File>brhc10034972_ex10-1.htm</File>
    <File>brhc10034972_ex10-2.htm</File>
    <File>brhc10034972_ex10-3.htm</File>
    <File>brhc10034972_ex10-4.htm</File>
    <File>brhc10034972_ex99-1.htm</File>
    <File>btx-20220306.xsd</File>
    <File>btx-20220306_lab.xml</File>
    <File>btx-20220306_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc10034972_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "brhc10034972_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "btx-20220306_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "btx-20220306_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "btx-20220306.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 29,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 118,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "btx",
   "nsuri": "http://brooklynitx.com/20220306",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10034972_8k.htm",
      "contextRef": "c20220306to20220306",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://brooklynitx.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc10034972_8k.htm",
      "contextRef": "c20220306to20220306",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://brooklynitx.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001140361-22-008622-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-22-008622-xbrl.zip
M4$L#!!0    ( *F":532>_6 4A@  **H   3    8G)H8S$P,#,T.3<R7SAK
M+FAT;>T]:W/;.)+?K^K^ TZS.^M4Z<&G2#J.JQ+;F?%.'B[;4SMW7[9  I2P
MH4@M2=G6_OKK!OB21-FR(SNV1YFIA!) H-'O;C2@@W$^B<C-)(JS_1L_C<2[
MSCC/I_N#P?7U=1^_Z2?I:&!HFCD0<9;3.."=HG\DXF^W=,=FGV95]YN5_M>F
M[*U[GC>0K5773+1UA&'UP1^?/UT$8SZAO65X<'I6O]B$9CA0C657D266H3NW
M+5;UJ%ZX6==71\0 \/R/#^>?ZNYY>_^ZZR!/:9R%23JAN4AB',GN:4;/&#8&
MZ64\6!@(/O='R=6=X[@]4R_'F66]$:73:IR09KX$IFB 5PR]I^F-5QA?PF,Y
M+S3([M78>;H6B=X 6LN.03*+\W3>/FK1N#!R,$M3'@?KWBA:%UZ)J0BR]OZR
M::%S)H+VKM"PV#&?IFMZ0LM"5WX3C-N[8LOBJ&F^2A#XLHT8>=K+YU.>M6,:
MF@?8C&]J^&8]B9_7;.NG2?(MFL<BO^D'R01[&YJIE=RV7C!10W0.__N_"#D8
M<\KD$SSG(H_XX<% _5M\^3^]'ODD AYGG)$\V2<?TH2R5+ 1)Q]%#-(J:$0N
MDFB&O)IUR6D<]-6[\L]Q$LPF/,Y)D'*:PQBS3,0C<G+\R_OS4 #+CS)R=OX5
M'CEQ^SK\IS7>/DJF\U2,QCD!R&W2([C&)@B]7@GHA.>4X(I[_-\S<?6N<Y3$
M.4S<NP1,=DB@/KWKY/PF'T@,D &\>S H4 "/?L+F),OG$7_7":%_+Z03$<WW
MR=\NQ81GY N_)N?)A,9_>TMD>R;^P_>)KDWSMP3'[=%(C.)]$O$0O@F2*$GW
MR4^:_/.6^#3X-DI!,%BO; KEG[=(C ,FKHA@[SK'%V<?!>J!7P5C/.Z4$#&1
M32,*T,1)S.&5 W&SC[#S5#W*WO(1.GP!I*<B(#&=X*M<[+\'*C"DQ,>(CCIR
MIH\TR/\Y#*C.'$\+J&U9+K4].]"XIU%/<QDU.2U0=Y.?\_!=)RB9+$]J=E.J
MZET'U-N^GR01IW%(([ 3A_*?@\$"3.M!/(F!]>9' &-*H].8\9O?^+P!JJMY
MCA;X%O<]:CE>Z )\NF:[ONO[)K/LNT$]1$HXEFM[Q@I4@T4DICSDJ)!X=GB
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M$W-DVMC+/Y\!HUJ&78C3TAX^;MWOZ0XY^GA.#%/K0\?'L)H[<=FFN%PDX.@
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M1!RI PN_016(DMB,$@B%/ZD@Y+W56!Q\\LKTZZ:>YOEL$^(!,OZIH(.46;%
M+:7H3(4QQ2FX))EB:6Y(@ULQ5K^GZ9?EP#A8>YV59KR4-4OTYL-!6]8<OMS&
MBJ&<*T01!0-.TTQB6@A677TJ3O_7G,]Z9/)9GV=%B14!K[/U8J38\]8H9GN?
MC(WDP2A?P]$<0A:ZI8GT=.>K3X.20>HZQP"NZ=2QWU1:Q@.(GR=A-I)--&,\
M</.,^W>\Q$HUDQ;Y4+E^?W+HV1W*H8<@!@<QGCX$,?YZO,*5N6QPPC<#+,)G
M[BSRO-,4'5-"TD-&#5E-C\<(=N%%WOC!J$Y!*Z&\VMO/^<=?0\/G4V'[4EZS
M3UEE6?D.;L:KPE'H9LP_$85$$]Y&+X,K8+)9VWQ";0HREW5%*:YQI8X'\J11
MI31(TS 1#A1EP1)$%B;K$N0Z5@;B6/!OJD!\ZG#$['(&X-/<<@/6HBG*O=(S
M/!>4A17(9?(.P$Q<_A7AAU-4()CT)W0JGNY=<2K@@8=3\0F=BI/# Y!H2Q!P
M[RF?Z5/)#//G?W/E#<GUU,IZ)_R5C)^B#A"RC^L6+W%2)Q8K/4&.XX)C=UNS
M])>D]\T=ZV$IAX$/5Q=[KTW+ANJ83X7*P%B3DVP3J@ER6 =LC(]3S;#K<F1+
M&9QG \7AWN/'N#?'7B2>_/3*P*,'A7WOHRO&5I@W'\ _:Q*]K)BQD5%R<*D1
M6,,-5<"_CWF-'-SM3PJO>  _=#S P^ =<3LE(Y&R,[BW9P23Q5"DC*2PS HN
MP.L7KK<N"!14FH%^M<RG#+5(_:)8WW)O==E3"'4QW*5L)+&@@AU1713[1>)I
M$VH.T")5"H"V$F)ZSNJR5% O^-"@QCAB7&2@E%(1',%R;RV*:H6)77,#$8MM
MT/JK\G0,*\@VQ",5]RSZ@BOPISW(>+Z7B#' !.T/1(54.LKL4]'*M&AI,^"_
MJVU:1S5J%M>52$Y!I28/=[IL/<<CY"E*_6,S1WX>?P.ZC=DF$MS+69Q)P[[I
M'4&NWP_S$T=:_L39B+9Z*]G*WRIN_ Q]I547?+Y-1T6;'.KR^[T.DQ<O#H).
MAQM225[6%WE9KJ[HC\@:FSZ;V)>ER8MN1E^<AH3S$@_&(]H<-3#TIY)<8I">
M-C@_@PX57(8(![98^GX..L[/6?,F)V@JUP2@XX\>(@[O%G'X_"'B\)>Z:7Q#
M-LH38= >Z&E!WVD#N&!6S]OP7D:F%K#25E+Z?E_5"L\@%S(HGP==Y?<59DK4
M"$X)?WWY+^S[N\A!7<BD$^/+K)UEOR<'4GO*"PD^^K&L)QL_.:&N),HEI+[5
MX<@)C+1:'EOJQO,]8TT&JZ43:$4UK.@3T4H&^Q!LL,5[XCWR%(D_:6-D*ATK
M?D ],N> LT#9*JXF.T6H/%FCSA'T^LPU4:BE%2?_YAHI7 =" _N#(<@'^6$^
M,3?,J:*&79$9"BH/T+,ARQ9$-:RO!YC_DK!M+9)=!$D6HR\X?!*]G9N_\&EL
MR#]! R;;[AB9JKFH=U^,2E@/GTJ2U#]_'2P]%P?$7 0%2K)4]=,I.I20:-Q=
MVMG?C,;1>+A,+V:G9;9J<\'Q(!,M;[\AC*5BH':A( Y7]64L@=R&XCX528NP
M#@)&R HAFFO8=OHL,N6#-SF0(A+56R(VJQR])IUTBB%K##[N@=>JK'66V+BV
M,+R<#'&0,,3#0;(?RKI>$"[VBYW7.\G6A)PTP9H1+Y>B<E]_\V03VBP<[:??
M/-Y+EF-/;!/2DEBNL >O3@_^ZP><&O[PWWW\8$OL$3(;<(R[HG8TJZP-S'L$
MS1DY/CCY89I':EK\!G0NS7D);6)@2OWHR.AI:+=U?"Q<[G51O4E>H8DFYX.4
M+=/*[@RXT1\N:U9J-(C7\^K12PNB>KZJ?'D/OPL_Y:EM\TXL:JH\12,KF10S
M(;UKR#*X"6WM9N[ 13&U&S%J."D7CITH+O.L:$1%EIXOA$SC!K<#FS+-@#M(
M[4R^S(D+$D)15K2$:(4J*RLCU+ <7@=ZR&!&CL$R0N>?E.0.8)32UE@H*PXN
MC<!J!G*75IR+NS1_"Q.6ULW2KR;P[/F@]J<C@]^]+X53B+V1,?NT"SUN44@3
MWK?-A31W053QX=R86J%[9E*7,UCZ_O'IT<&+P^3HJ#>E]_[NU[\<'_RTC];W
MRV?)R?Z+P_=STF[9EWXD>K:WL^M."".]7/=_WTN0\7UT[E1/^JNJ5X6JT1;2
M'!PGIMN18V^_4$,*<+ROUVN +6,!9HPM>P?M*#VQ?>PA,27 ;./Y1H,^0U7A
MXH( !@Y/\3V0@Z5/B0C2V;%ZF)N_8B0-E!JJ_$3>2E^GQH3R/,Y2(,M\- O6
M\K?=O03VH92E#40$E>POZPX= 49RKH$0\ -/WZP0%*@&^7OMR< T[!S$MHFR
M>7V 418(M*XN"8YPVN0<7_ 0DOWHW%#/Q:VN/N,B(@9C'/ZF@U5OG54MV'MH
M/')+WRQ!ERG2;GQ UY9X/O(F3PC_RFUIJC9%VV=LA@R*1XV "9\/JX>5>8\D
M>A"N)&J+]- /?H!7;H 7IFBK;ESZG%_/0CMI4[^(Z7E-@+(##[%;T9RSP1!F
M@9IVOO)4B)*H YUPN*DN5A#N4 _DN^LKOIDTHYX#X"Q/=[[^^N^HNJ=:!DF$
M</S!W%-\0%A5FGR-W]LV@'9\,PR(J=O3GF9NM5;+J#CJ>%90SJ0D1"ILHD$L
MCA3ANL]$]:(?!4U&@\7Y%G?#^\PWMUPK502M.*;)3G*8^?3#Q!"+*>RZH$8J
M^$61A=VR&9]XBE"VE)LP/<^ISZ E3Q3V=TW!;L!-,LNMA[,;Q,_J/*C:*L D
M9D2(,[Q63P2SZ"@="SDBG(JE=/ P/#I3VJ?7OD3]>9 ]$[XQV@;<2>)]!?4O
M#VHKS.CZ!:)V6!ZL9^L7%)7<K3:S]\63 :LP*I=>.2@O_5M;>BT^N+?S) U.
MM."J$L1%DR]J.@QX@-R!YA[M%H*96@'+]\U:6N62Y.&2'L(ROF.2BQ5BX94B
MN7<&@H</L==KQUZ_>(B];M@YM%'_3,MB[QTM"_N_'Z>1\8PO>9C]_8YW]]T=
M#;=>";#U#[U%GWW_2N "1H""TE#E"82@DS0(G4/J,"<J!O 3D8@*(@C?_(E;
M]N7>G6Q9\1%L692/2?TDC 8SN&/?WD-2OS.M;UL4GD6]J-A60S)ZVFK'*T);
MIV+TC?YH[P"XESOQ#EMQ^TW09F%D$S5-?E%3C,CO@79$U'8MXA@R,7[_B/<;
MV8^IU01QJY2;.5*(8$9YE9.L17Q^9ZA,*9.8$-VFY&4P!J H]^]BI<P*;C2@
M$9(1U+K4]10,BA/$$J7\[=B-@?KOH*4;/R:+<@:G-4#'5B*M!6VR^7E>4MCG
MV?$):%[UFT= X88S1W5U$?FE1L@O:^-J)#5;)QL98I.@T9HS5NIFW=^0^W@'
M+VYR!6][^?K9]3V_@:?\=7<P<#B)7W/0B1(X4-R=HI2 8@ZGA[9?F[AN[6^_
MA^O&#5Q^V(X</=KT4>U'PXM,75:\;/2"WL)K&) #VZU,LW*Z*K5B./)5N 1'
M?:I0IU&@NV$K=T0(+%E-:_+2]OV0-C])/2D5#(KJC!0=2KONS M$86F,B]!9
MUMS>'=[G\].E*Y8X:XM*W2.<^H;HA:Q +FH*QV?5=7RA[-G-JKAFPYV;OSW>
M>?SX\S" ;DEJ 3\MTF?''O)WY!4//@'V"7SYX!/XB*3(GRI$G)MS7$+8B-L=
MB@K<11=O62VNUF.0\XT"8J97LYC=G:]WQ_A(X(:^'5/YH$?GFC9 <C>'IR^Q
M2*!H7RY_<"('@\MZCFNR* )A+0;2^/459=[!^<121DD4\@$!&NR\R.?)(8>3
M81JO&& >I2!_]+RH0&,F&<4?W<L=OI&9=Q<[W,N0;[]%^M]+VEWW?MP!V3;6
M'IC85.09BI+;[IN[=/(1^-ZN[R[=&)O;Y#'MIR\^^$O_''_I_7<2_*D,_!I6
MM\F@8?,;F%"4"C#?&/>7^X 8U:M>D8R!-\".D9@C ?<PY'/W5)Y\$)?K;41+
M>!CN0+K\V>'2)Q\DV/"^$S'A&F@JQCV.E8YAXGSX .K(S##CS?O.>GWBO=M\
MI&13=P_=55$NJJF_\EDVDYSJGO/NTU 1[H+199ACE$W76B>SD.9+UJ]-WLF6
M,P:UIS.GPS;Y$CZ&GW2#&VV_H%VTT3<@T#MK-SAU9&F2D>Y9J<Y%W[S-(#.+
M;):K;S?6./5HQ1,BA!H_HSB7CPN!,\HZDTS@K555YJU)>LVD2$>D[)3SM,6#
MX7LT3Z5/N_$L,VT1P*AUOA>J__K+ZU1WZC_#3#7/1-(PR<[LDR\%!V)'=D>C
M<+\"(I4W@N22=1LM&>MTF6"<Q7WS0:.Z&:,1XVZ-?"#:G#BC>'.B)AC _3J&
M^R;*/Q([_I18IDO.[<OJ@33G]D%N/\CM#R.W57$<$]H&CC7Y6(3V0P24(Z!?
M/41 /R:N=<_4.7O[WX,N=P_%SL>@Q]E=N:$2EPTH<?=Q&VZ42G!GN]#T#W-5
M.[ELW,V!@&8%S64;U:$3N<!T,MIAC_]Y3XV<#[ IW$\BI%[$A/RV<-6W0K44
M+C'-()DXB&N_P^VJ77(OBW[7"8_F$D3['>)F#^P&]I628G'KJ0W&>##/3K3U
M19AG>:4%W!NQ?L*EV$S58$WP<H%RI8*U15$5B]5"X6J&Z)&WF%M>M.>,4V.F
M=GF./39PVJ+-VNF11@=VS 6E$V.CX(JH$%.HJC5<F8&HK]Z0B8*8L753P,3\
M/&;YM,Q0'N4%U1G*[H00SS 8G!>_>H$N)$5SU9W7,G/_4K[E]!:J R2,WLKK
MXEA22\H2#IVWTTQR'.'8P>H[3#4L^+U<_<C]MKG#,V',N#_@5Q?2))F(L\C.
M8.X(+"P5[5*8JQ77=A:9<!BI0RP(3G>=S%TBB$#LD+YMXL)%4*<K5\!E+N?
M,F9G"P&$BS.@%]D;6%G1)<5BV6 E)N7G\L)@/D6K&:@N=RJJ'X[*.V_/X-X3
MC,@'P!$Y/GQ]?'AR^/)T__3HU<L3@A/Y=?_X>/_EZ='AR7T"%7GRSJ B[SLL
M<A?=R_KF\J]CYK*->"%.:KZ,LO'D]IFV/(I$CW]^5K185HS%XB>*TJE5"$.?
M>5-:6C-D5'8L,M$H^"[-FGT-ZX25>[LRQ[ZX2AD="2%@A_@S%)S<3\>["#8N
M(PY'D;/C#6-M&5_5%>Z)7H'?G^G'^M!5F+?N/7KKVW!B<.0'('?VT>+4 T+
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M H2K=@^5D6V 0;&6%)?4HL)&7-07!SL.3+CM ]+']Y6@I*XUG#]+#Z>N\SE
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M4.7Q:9BI9(R3D5IF/-"KCOQ]E!B![%TN*OHC^;>C"DF<SP;@A8.^7V':42H
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MI3ERBEAQOG^P5($LZIF#[T]-VXV;ER*.UAA^:T BKKP/QAD,QX/DM53!&X:
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M?/A?OQP=AW93-!7<41R8*$&[0ON^__KUBZ,#G)#LF_G:B_U?3QR$:'"@D(1
MOM<O#I_]>$CC'KQZ^?*09\OC)C^\>KF?/#]Z=@A/'_\HK_X%",&?Z_K-0?SA
M^-5_'AX_>G:X_P+("81@D_#%JWTWZ/.CES#WH_T7\,Z3TZ/37^B-IS_MGR9'
M>&KU-,"[8,2C4YK</P]/3E\=:U8VG)]GAS .S_OX%U@YIX]OW$8S%?H0IPM'
M_9>#G\S#M['C;\;-WZ>_S>H^J$US6(AB337_*YIY8". ;*PPVC_+9;H\YL(U
M37&:O2D>G#3U&Y"TLSPKV2+@'G69;P&CS<R1[[8(E8)*=UD.)S#8; .3E^_C
M-M5MR@O&RP,H#[F8>_'BGW0ZJZUP,Q5U/7<Z4MQI[$QH<EP214*57$,B])#X
MFN0I I?,VR#+*--]JQO_!M>A""T-BTN'+8XNLC*.4 J^+ <2C*W$?U"+23/,
M>69I,"V7XU++^G#:WM81"H:F(5EN>(IT0<]737?.2)2:C=L?0RT:GD94&.-[
M..4#CF!)_PI-2RI=$2^JA4;@MY@T,G7 NJ0C)7T>[]':5'U&/@%C]N&*Y [T
M[.6A3>U=CB!V5/1SG)I@[P.S<&--8VSPI)J!3Q%-+6[P37C9ZRW;HRF#*P=2
M02WNF&48I,*G>T]!]]RZHCZ'?1>F8M+5K8^4C>HAYS. QCO%"/#)LF@[=HUP
MA3#U+,7&%:AS;H4,XDJ:;//I56S$!TOP72S!+QXLP8_($GR'RLG;9C5A^A&#
M5, G.?KN."F&+C9%8@(H7JTYE,],1%""1\2*Q-:+@LOR5Y^>T/,X2L8)5A%B
MG^3SHN20TY!G-!Y]N"9\F_,+]"'?))R;(SMMJ#6>6,<-!VM,".^:<L.]J4I^
M.#NP4 ?89T0OR_6U<!$Y7[M:4 0N:\\)]<NUA!8>JZ6>1!I"&KGJ32A[7+/T
MN:106?9_]9O#^B\W!9<D@7^EE%G"7%JXU!(*97(;K:B#L>M&$ 9A=3YP ;AN
M%/L/Z@KEV!2!BU550=M5H-_KH >B[(_,;_"/Z+/ U$"RFF"Q<94WM>_,W#)
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M4R78JI7B<Y,'U<O%#,F>;%$F7OT&L1P;HT2$V[4=[@IK<+PUZHBBZT-^-;Q
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M@>\C>IASQ34K;9@-\UV5!N:HZN5BLGDC;6#"!5-F!I?!^OKP )-9TP T-"Z
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M]B_SC*T$//'H.%KRLM',_87C7BD[.V&(R-;3+B(=Z\D^RP/QK];Y9$I/HCL
M^H)8G)9$L\:AGI-.<=[NSSA,AW>-O1R=6* +LI0\2.#0;]\B!C4SEN)>PW0(
MBVZGL* $OR14[I=0>?.24'EB]^(/4[)YDE5]MO.0"M%H@T&9WAC#!7O#1E'@
M+1SY09FXSYF_HGDI+,\5V:-F@&GIATI6=?RS$8B/TC""08[\%C[0TO%&I109
MZE"S=2[XODJIN50Q<0T)J0:E$:4)D8FN!:#TCJ>*<8Z*D,;741N8/L>PA5>J
MYDM84"X4" KA-\SHV<_'?L3PAG<+,>/PUJHP!BM$H,T5B]RYV*06R>2)99@
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MT3+6X2UB9&1]B67X5^NLRR&OP;^?ET7Q;30;Y_5?Z_WBZI$TUN/=%8^[3F<
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M"SCDII)5D23!.M5M=-^#*CKXKUY.QM1[;%ZLWN/>RW!ZGFMQI&0&WV6?..(
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M)]7Z5CL$+K9#FI"PZ(]NNN7UB0+7;^*<&*GT!W_8XX*&=0Y&=O-,HL8D^#S
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ME]I0(DGDA1TX%4\Y?Z; 5CT);D^[XCL=4&,6!,W$9V(UK;J"3>:,JG@P5(/
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M7(3U*V6"XG\)/WV17;\KLW#.]G^K3>A 1/YSGM9VD!$8$871&>1ZV4B[P80
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MW['V'XZUOZP1>"U5.VN/!M=4&3Y_"78B-?>"(;E7G*9U4_9-/=/^(G8,%Z;
M,':WR.064F]H* F.9)).#.S6@87VC78P"C"=Y\?QLO%<Z+IN/'OXD&?[<6]/
M-R[PQ4S0_SW<^\O^UM&' \KK_/KNS<[NP?]YSW0KN=8ZI=MI9)+D"!_9?8D[
M,&>A;[*+O<-8C+&2-'CZY872!>3#][.%#S=[M_!JG6_!:EE7+ NLH4'XZ?.2
MR[<#+$,2:65%\O2.=;[(Z=\X]_2'MGA5"?#3L[MM_,I"G(IY>O=QU?-X)\J_
MS$;VV\\[8&.M>NR>/;[-N]4M6O(JY986_-QT(=@?O7J*X"NNJ7AJ]V^_[KW:
M.XI>75.S3Z@/_Q+VOS^M_>W39SRM?>L0_8*WN_M'T>MW!V^_PL(N&(7G(J1K
M>7;(T/-]W8VG(=IM/-EDXK&P6#LJ!4?$GP_@H!NEY823U53*0$W#\]DL7SC,
M.355OH4UM%,R6&^M;^'C@J5!6# >8_2@T]+E$;;ULJMGJJ]S*U8B^T,F.S!J
M]-O6FP^[T<'N]N[>;[L[PS#EB<P*.LK!T30&&*E*+492+6&"IKQPEOB+J>&0
M\ QU_*RV34LJ'SLQP*NV8G24Z?6'.'HKZ)=7-YK:\][^CZMW2W0]A L1SW78
M]'?5="R1*VWBA5ZFEW)?9-?7I)[D?945S>#2V]_;>? UB-]MH;CJ1EP#;WX%
M2O0<!]UD]@4X;"M)<);Z5Q0M*[;57:.86>6)U\SUWB.O_01\::;YDF+I:V_6
MM>B*Z^;QKTRAVR&ZKEJJ>5(6J:O&NF3[R)T4O#M8-WVPOH'#M$MH/\Z8^,JG
MZ;(J]M:[+G<GZ%S_X@L<%@S<)\]M=Y?\![\/Y;/KY_ROYN6X&/[2%D$_J/='
M#!I1D=@-"O4KRVA_AE!DD_Y7%M</>]79#427+D;E51C^8AKH@F LMU;']++K
MI35"+QM<^H[]2[R@CODCJ,1O3?ZTC<4@LLJ=1/H>)-)Y-H3Z2>>25_M8;A;,
MTPN.'&=UK9%QV3Q\*%'L=2,31(3YJ.*'\&?,=H@!4Z0JA__B1QR03#^<--,<
M?OC_4$L#!!0    ( *F":51!D&C@[TD  *VH 0 7    8G)H8S$P,#,T.3<R
M7V5X,3 M,RYH=&WM?6MSVT:6]O>MVO^ ]4QVQ;=H11??X[A*EN6)=FS9*\G)
M3&UM38$$*"$& 0X 2E9^_7MNW7T::%#4S98\RNPF$D4TND]WG_MYSLOC9IJ_
M^O=_BZ*7QVF<T$_P<Y,U>?KJY8_\7_GP/QX^C-YEX[2HTR1JRA?1P7PZS9IA
M%$>OJS).JBPY2J/M<CJ+BS-^AOYY4X[GT[1HHG&5Q@T\.Z^SXBC:>?.7K?U)
MEL//=?1Q_P/\F$;/5M?A?VOJZ>UR=E9E1\=-M/[\^>/H8;2QMK&A7_CP(<__
M1UG RU&9G$6CHW&9E]7/#_XTH7\>1'5SEJ<_/YB41?-P$D^S_.Q%]%^'V32M
MH[WT--HOIW'Q7S]%]/<Z^R-]$:VOS9J?HB;]TCR,\^RH>!'EZ00^H9%?1']:
MHW]^>B#TJZ*BK(_C!%XB/SR(Z+F?'P#1FK2R<SA.<4$OHD>S+YW1HE$\_GQ4
ME?,B>=C^DYX*#_E3-(VKHZQXB#-[$<7SIK0?5?P2_FQ45DD*8Q5ED9H9)]F)
M1Y53F=:HS!/_9304/+;SY3@;9; 5:ZN;+T>5$![&L0.:P^)^]%_4I>:%-Z0[
MUP>O(C,;>M^/R[R=UW0]K]_YV\[VI\/=#WO1KSO[!_!?/07OYT6D>/#J/_^T
M_F3MIV4>^'U>-]GD[.+S?_!J;V?W\)>=_>CPE]V#Z  FOK][^/=H[P-^LF,^
MV-TYB-["1[_]LKO]2^NK\#,L>'][]V#K];N=Z)>M7W>BUSL[>]'^SE]V#PYW
M]G?>1+_!.]KC;>V]@0>W?]G:^\M.M/WA_?O= Z15U'FSV3K]G;?P^-^C@\.M
MPYUH%U_U;G=K;WLG^O01_KJUAS-Z_Y&VX.W^A_<RE?TM^N33WIN=SNJVM@]Q
MU/7GFYO#: M^?[\#7WL3K>#W_O-/SS8VUG[ROTX?KO\T&.)*X%_;VQ_VW^SN
M_>7=WX?1^RTDX2'0 09]2R2 91U\>$=+WOEX&'W\M'_P:6OO,#K\0/.%;VT?
M[@+IO*G2 F$FAV[2AAKMN>^WA]SZ=6OW'6V)3XPA?A=HMA7!6_8.X&'\"\[V
MX-/K_X99P/-#(H\WE?V=__FTNT^3.4!*!>B'.XH#$R5H.VC?MSY^?+>[33/A
M#5./O=OZ[6"5SWGK6.%@K7? YG_"80P):+/E[.WPG/0(N FP 1_?@6S9H9EM
M?]C;V^'U\LRBUQ_VMJ*WNV]VX-O[?Y')?]HC>GZ@>_'N ]"2QH0Q7L.9^P0W
MP$UJM7T]7SG>L\S--8S[6A@/WA Z-1^V_XK' 2X7$.:WK7W8Z,/;--'7^Q\^
M_/7=W_>BW??O/^T1H;<^[@#/W#X8PD9M=ZD:X(5-/ (=89SF>3V+QZ X_/Q@
M[0']/HN3Q/S.HHY^S)*?'_RQ'H^3))ULQ/&SYX_6XWBT,=Y\_NP9_/1X;?WI
ML_'E58.V?#[-DN88_[CV@\A8_,<I,R\;)Z3X]\2\6QY]ZCVYA/A\\.HE3LM;
M0F<O^M?TX-5O<57%,,#!<5RE]8OHR?#9XZ?#]4<;+W_$9U_YPI3/3I.<LXQ-
M6L859[9;U_,T>@,JXPOA%^_C:GP</1^2#FCGY\T&?JU:E(>/\-Q<_B)864L?
M9D4"%P.V:F.)503$+[&LA?<V6FF.4R."KDC$EW.SPR]_G+\2FAE!!E>G@I5E
M\%!S'(,F/RDK0[N3. ?J5^DXS4[2!*1=-<V #&/0\.-9UL0Y[$8-_"%Z"YIJ
M]*Y)5J.RBK*FCN*Z!K+5U[R*7X"/I%5H$5D=P8:@I0+3G,_*(L(7P]2F,!>8
M6ST?_9Z.&S!9Z ]Y!D9+W&0E3!&^FWY)JW%6I_15_/NX+)*,_FQ(<9Q6:5;$
M$UQMG39(I>88S)X&GCF+&I@N#@2KEZ]D7Z*5)X-H"K,\KJ-L.DV3#$YQ?@9/
MYGEYBM8/OBF!#VGP<G+-Q-HM8 6P13MF<7B+0K3#1?/<9U4&_P8:/7ZQMA;-
M5J>KT0H.^_>R^AQM9XVUZ'"] WSH()TUZ70$*^8;^?2:%W$(.PADQZWHG?]H
MWH!)TR YP;A$\@]Q#;#E];C*1BGN%2UR-@?6$0,E)E4Y1?.Q_)R?%='N=#HO
MRD-X.IZE<SC>-4BC8KR*1NV;-(]/@2G"B:AF9<43N=XEBK$<6!F>9%R)9<=1
M30PZ6HEK?:+C!+D3F==( KB+1((;X!\B(4*[4$ZLQEY.IW@TFG+\V6IY,!E+
M?CAFP$+@P(,=RDO"7_1C$:T!E@#WVKP:OICG$6QG^L\Y'&NYR?9T?\1!8<OJ
M".1\5J1)E.'Q'-..;:R,!DMI%Q?B_IM/9M<@?(&Z9IKK2-A52UF<W>7^?=4I
M77E%;W /F(.JPV).@T@/&#,1'CU'?Q+>4;S()=[D4]Q4LY7,?>4(',<G*>W]
M-(T+\AQ9AHQ[CE*,A%K,!V!>P3Q@BA_-\=LZJM*4;LOU7N3N"X)W.B'_%ZLQ
M3UB-@6,+1Y\%@K #*XK,K:E@F7 6XZ:LSIC5->5J0#^[G2=[8YF3'87^XWWA
MFY]KPV[TH;[13?!]>]>S+_$@L!']5+^=.X BHZO5&@ZCOZ5O$7O\:M!I9R#'
MT+A-HM&9+VBF\1F*F6F<@#P!'G)Z7(+%B8IM$<WBJFEI?17]M_;4/WQE4/]2
MRM8H!99%C,Q9+FUU!^>6I#EHWWCI2X]!P,KB*)F#1@GJZWB.*YG$XQHT6[2/
MR]D9ON3CF[?\,Z@+H/+*<M.'TSC+HQ7X@OP8-TT\/D:>-3 DVRL;$=-V!1FK
MU3#O*2RD@/<R:X:972\K[;X[P$K-7O^6P?;QS-*XRC.@/RK3V2!J3F%B&X/H
ML(K1,P D/6-S8"7#O\(#Q9R45_B^]YTQT+C*:J.D'S3P4%PE($X:,#%(=GQ,
M05E.2!4+*AS) &? @FL04OKAG<[NJ-T9B/%8U'&6L K'-H^(/CD+](?X",3,
M$8[DZT"D[N(7?)TMJF?I&.V\Q&QC/)OEV9C<*8&]AF-RFN'YA#'J"=*HBL9Q
M?0SDQ0U8?_H3D.DX!5TMJ>+3 @]U''V",P\O 'HU\,917'P&';;(T[IFLPJ>
MIU_LPF=5.4Z3>:7N@#=/1\\Q*/HIT!!-O8LM9?5*YS'HR3+,D _D7@GS^/RP
M!-X"ES</4=,JKQ5HKT!6V-RB-+OJA<K 4(3/<,U'\QCW+TWIHI)2%#5G,QK8
M_:W$D%,35]D?Q#;H^B)["&VI>_VJS_3ARZ=PBVH\YWA(80"\4T=&\1+6 V8Q
M'(?J+' R46]3X^,3L^.S&C8ESY'[5%7:5>E;'&T.%GSN**'> :S;LG#0$^%]
MPJ1:9SP^ 69&Q\ :0E:1,E_%L49IZJQ^.D63>9X+M\] ,8.3F@96N=PZ)G15
M"O1),BL_-1RJPLW<;#$D60HSA<*MGV="#+?O6&6U80E,<C6+U>@CR"H40&:=
M\B8U;R#9/&]P(BC:A+XU2Q:P=FGN,KNF1'>/8Y=+$+ZEK:>3"=JK\"S<8F">
MP@O+>6./'0_O*-!]CTRR]2:8?5R@#@TGR#</%6/HG;L]6-I8E6TWA\=L+:\)
M1&9!YD65CLLJ 89T[)C[^>^QHQHY4,]AHRW]5W$"C@C^JXT$( V / "X2>@$
M"-]Y.7IH::^L>P</OT:NO5ECYU#0 *M7T_*"'+-%4[)PR$>8PCT#61./Q^FL
MP4NC/ G,!=R!!<UK_+DH3_,4@_XT#II:XKB$4:HTKMV9!>%R D*<G'QR\D%_
M@T?BV?&P)9*M@A@Z_*V-;#E9EK@4R!'L&Q1K8CWR"':T8&V2=4^]?A&>L0@Z
M/N-U0T:DN#E![3,^1&>,7,@FP1C)FX./;S_&1^EK(.+G+?B7C8F,<]"K<">;
M8VN/-.7,' ?Y!/[<E%/KXO9"[YWQ[=@S^.3A"#]Z2*KS"^#NI\ 5O0A(.*]"
M1N!0ST.).JQ1.D5WPI1HP7_5$9K(I&%L7"P-X\&KWNC^?SQ\*)DLN-H].AS[
M8&LT/\#//VS\\,,/DJUR:^S!4<@>7.;?M\@:)-4W8 @BWU':)K+'&<NF"WH=
MKY\E_EFFNK[Z?-UY<Y4AX-RZL?9QB4YVO197+R&MM77GW!SC\X[U;78T;1M3
M*>1QDDGN3E""D'9&G@AE4$I$B?R$J"46I>A?(&I 2AYE=2/!#!(E=,CX8]+,
MAI'8D"!"T=AJYC4I_S'9N8V<0!JW:8DY? KMUSQM24]WL$4\DM_%: 4D2HNN
M(R;.ZY*<_D99[W?)D 9#E("1T3<LFJS<D8[Q*2?;*?T==1_?*U%%5+$D$ I#
M]HI\3_G\YQS4*:1L.1+*C92A!Y<D(UWL?U>V'KX>1"M_&_P?SGQE:S"$"0&)
M7]S4E7NX\;1SYYX_OUPH&Z8;_8P,RJG:+]CY A3X];>MCT9+T:JGCH?.D*Q)
MVS5ROH,B8YW5$#1L':'.BVJ \Y&AUNAL)E#*ZKF8<,[7$ _,!2*O1A*?<53!
M''A?C:[(QW3EM^@Q;2"6+*19BF$.7)H<9;BI\SRNT#>#C]@8=0GO,:>ZY9C:
MGP,5GZRMK8S(0[!/(]!$]MX?X#6?SO,CSLP5(0C7.86?X#C7+HB2QZ<U!7[I
MLJDI#]FG)ORHG&GUV=SP-",?QLK9C1P.0P5] G!O_N"WO<X2\8_) )[DEVD
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MU$*7F^KP86P&YG=AM(PK?C )C7/S0TGI!MPE*:? 4?/4A)NUS;1BT#+$!L(
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M.B*U[?;K+J=Z8*]2:.O++F)2+\*;::W+N#CDW9 *2P(EE@/6QX1]-<QO>*-
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M5IS@1MMA'LN5@-12IZ3_ALIBD.5@(AXKCE@A)P/R!%([:,<X8@4K'E$<+64
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M=2BHZA4CQ_.FM!]5_!+^C,\31O>+5,6[7_Z(+5+IA^-FFL,/_Q]02P,$%
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MH03RCB2;YK?EFX<6M;[W?ZD3Z&]K4O</=GYL^W?@_(?_<M_#OS?OO!.C)$M
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MZP7J['MJOSU# 36J9Z,CN8L2EA8BA].QXNG)GU@;0DIE;>1RB)')-P7FBX3
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M]#-P@:<S5MK'6&T"&C*50" #.XM^,7RR4@[9'<SAD-W!FD.^4PZY$"GF@%R
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MDCV*0F;@0<3HM1XER6X &I;DIPXO7ION;FS:U.!"P:%@;[[9-(;#IFUV36%
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M:8SF7?9%-P)VS4OK3SZ'AG=6YZ:2$P"5.S[QUT#HS@)XP^>76M9[5=966C.
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M.P0()OUPGDEA1670T&2]$WR<4K\J,C$KV=."ZN=FJ]FQ$8''%4/SX E=6>N
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MS$ZPC>R-2X6YV^[$V_4T*%I0)&TDD+P(*T"&DJ]Z3E6,?I\$XCKJ]5/+F9.
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M=@E2H==*2_EUWVN8-7KVL?FG*B3T:8&I!6K&ERR_Q<*E'F358>J*NQST@DZ
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MEW*\=8BHJ,$/I&0QN&GU9GX: $YCN7&6.\DPKH8) UAN*CH"6QY181^<$0F
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MN[0YO;U*6T[50:4<J5U"J%F9.RH4[DA 7#;U=1S.;(RBT/X0RC;Y$\[NLS?
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M6?I,FWQ,VI=^N[+*'W<90ZF[0#3]<TVY?VQ&5);$_3AP9_OXX#ERX'<O:4Y
M5UI>S"Q1'.]3*M& KT$=K!7A^8KPP5H17HRU5N&O\%X9/\T]"UC);*=_/WW[
MQ^79IX_!?YV>7\C_=AW\0RTB<%_E9W@HU #E[3U]72L-I;_]]/OGDX___9R6
MY$O^IU[!Z&+YVU24X+'(PJ00S\IM"'X<JBJ 3B=Q(Y+8\$VM%G3DG%W/8'>;
M]!X/^(B5'C6"LM+\2SK+@K/Q>)KE<@]%.!%32>ZR%YQET39X.]^)-+R%,'J4
M%Y.<O=NK73WGZ7JQ4DRI!I?OV(F]4!="D0&N,.0Z9RQ4MJ))I@1=,I%*;#.D
M>&MJ/5>^,1[8UTRG#0O@@7@#)[E0D_@6Q-D(=IRHEL+-T34K,7K0WV^I;[(P
M=YX.:H>7YK\?O390;-OU;Z72V=0XI^#EB0Y>/N"AU>?RG9WD>@LZ(\ZCJ<XF
MAI='Q*9]D,E#%'/VY.0BJUQFY][@-43W.N0P ]P 7]&0N[V;4F[,TM"K2-,@
M"B=)):7QOR#0BA0'A[E!L%#ILE0O#-:/_!)ZZ3$F2L5U4);.@5-,0\6*D?E;
M>UY!I[>J<$5<R0<CRK,2B(F95&$!I$#:,V1$.*8@;6BZ-UFOI6_S^M*;/%ZA
M(%-U%$X=#%X'.6HZZYF3_LU*HFE"7T!-AO>"8?I5&-]@I!A*E>7.IBD7*F,(
MRDWWA[)JN?>TEI;C$$1.9A,"8R'5 ]#&5T![7ZY9J:[T\=/EV=O39\7'<[6@
M!^]:YV]:UY3A-3[E,A$$0R)\(TRN%AV/A\F]2JINSGIF"=;?F0V^DG:8^IK<
M_TXPJW'R".56F'"XG9O(20/JE27]:P+U_JJ@V^07@&:,06U[@ 2;UDPE/XJ%
MV_H]AN3ZVQ^G%^ Q^'AR=KZP %NZOS"U.PC%Z#C:W]D9C X'AWN#<"_>&X[Z
M@R/1'^X<#H=/&(:LM5]>)LAH]R(N\MNVOL1M':%]9]+?7AC3U6XXO_SLC^ T
MAV#DG0!4'X;><]I /^C@[0,2XRXUY+= K8UP<Z6D6B4SO_KY/:12?D KH#.B
M_C"LO:#X8'EK=Y1?YM0>;I9%3TV):VMH;"(:UV7RZN[!RGE_)0,NSN8+/ X+
M4L6^9BO?T'T'WQB^,.EP;DK6?^/&X,D(+6+*V96?"@'W:9/2RC=U]3XYBSK,
M=JC9>+-*27._L[F+/'C:&9^9-'K6]^[9Z3#/FEH;T0N34A_#:@H@7&_EAXL\
M#3X3XL,&@P*($/I^!QE_BO$@;J_S%F2N($P9:AX]]N@Q+C$8-,EOJ6[S)B=8
MCC@I)WGI0SA3""'#67W[ ?G0G6#CYEH4OCQ1V)7RLV!>3]-Z=QRE6X>[ECL.
M/O FH!^MQ)#=U5YYCJ9 A([BX>BE]-@&=4?/"\O%'D"[&C$<#@^.!D.Q,XQV
M]H48[1T=]/=W=P^/[I.+O3C;\:(,^]W[.?F>5])Z"Y?VZ#T]E][92^>2W9?I
MW"%GN][GYIKOX*(6J9A<RR=UL4?.QTC'OB3]I43Z0V_2E[>]TCS2[Y>=!\^+
MG=^'7^_!R+X<\#4C?Q^,W.\_+TX&>PFZ>Y&]='>F/CK^[IGZI:C\>V[/CZUW
M! 0/R033<IDHKAWVOUOLM+]WO+<SV(>.P:.!V#\\WAL,=HX.]@[C>.=PN']\
M]XM?#^?;@L#EM3IG>[BDV:.R/L@<:K7R5L?P_C!2JXK=NI[FC^_K?CDI1##+
MIT'H8L'_;_^>_;?,+U;J!H;%8+7;YKEOS8D:^Y^3>Z"J6NZ<,?3?HN2[]>]_
M.3X<#'ZDO[7]6QK:[L?;"EM\^YJS]4=[8K^!F^8-R2Q]T^Y^H<Y&*F-M)C1<
M#SI?J'/#GI0%T$,@QFNG6L;-  2C+;Q"B+XB*RE/9X3>S1O!T#+#,$,,VE(4
M-\K38R4"M=SDE=S8^G5LO,O-N3UB[(5>9,\]75_MVC\KO=H?<TQ,>QZ7.\N]
M=WNXV5.7CTLYX&/]PQ]+*-@8C;@W20Q0WIB#'E8H!\IKQ,P!W'G0&PE(/,0^
MCE;[F*421SM(O,1-]VB*P1S%V)]7>I]4U=J=>FDUKIWM;9OILZTIMX'*N76E
M4%>";2V%%O-FFP?0EH![QWS;^66NG0_),Q2)=:'H%XM+",8%1&.+<&S7?+QA
M7O\76L7C?06D;\25F2BUGK:+FBQM1DO;ZU,7CC4G45,5\CW[7CM[N7OP,M6B
MSBW;#\=:$7(^L+ BY/%OMN1]Q$]L"KT,\2)U.I0NA9@G87J T@>?A4XAU&**
MU3?3_ZZC HB5-ZR7@^ZQIBGH<%HFF2@9FCW4[2YT(HH:W[__H+MNE1L:45.F
M'JX70+ZSW."-EHTV=^5]^MSYUW$G ?TH&NTB3M'O03S?AQ:-J,+SD^<N7YB5
M^C2Y5MGN!_1J5=;N8,WZO]2ALCV,5'VH41_<!H^?GPUNF*3]MUW2T:_6-Q75
MAL[24%;G>:WN6?CW^!&P@8Z F>KA3W;? KL&=^242'Y2);DM.-0KJ_IW]GX?
ME"#V+" .0@1H2M07)&P )VAPWS/)E\& +H1=5YJ4.NW?+KLNG*YV"HH&B%76
MR6@X2-&3&W-?AUD]>U9#*[O W@*P %&QZ89:J.,UK5T&JW 9+&Y(M$0O7[QG
MX64]?)>S">%:G8RA039"I^.-LRZ:O]U+BWSS9HC8O'2WQ^KQ?"TKJ?D^'A[M
MB/VCO4@,HL'HX.#X\.APY_AXO[^_L[M[<'B/O(7GE[#4FKY[[_+)XV=;/?D-
M;-KP^YW3E-:(H^OF\9T,\K1:_+[2XL^M)G.E@5AC%;,]HVU)[X37K?0LM4C[
M_KNK]?LA_$I9E^>BPW?1)O1>FNK4/NY#CKR 9?C 9F OR$3"5IEK_V6JU?NH
MUA,(0!"E!HF]@\CGFU.WY$F19%$RD58BM!^O9@'WGNFF0!!L&-BW_=?P[W%>
M:,<V#]4P+NVU;J+#!IL"HM<Y+Q/5%YV6"G_"CW#K2M**50-+3]]*VPFP =[M
M"CI,B5A$HBQYNX8BFT$\5=U YS6Y]#+!G$_<1PMO<Q_Z7$/XBTZIT56$^;I+
M-5ILD.-%!GG.2U]$Z*TBO1W=B<C*IA<](H%U6FR/2])EM>?%Z7Q?Y7F];=_V
M/*9WPS7LDS8+)3DNENW0^1(^"*(D!C@Q #HII+R'8&:6<^C6/ 'LX=0/1I(1
M#EZ$[U$1$ "T#N#:F'FZJ2.CSF(P 9JQY3""H5(Y'1(FJ?9\8A=)^!;,7N$"
M,.)[>PUHU!W HX48AXF4!V(T@I#'C?A1KZ)G,*]M*A 4+N&>(O!N4A# :CLM
MU)9YL58_.QL%,T5 5<?-9,]KM^1SE8SGA:?[BU1 Y+#PQ+/65-\)0LI:G1GC
MI(S2O)P:1<9FB@CJL&PLXH3:*8=9><M=P,$M7P9]C:^SK_!D+8H!IBBBC*L.
MA Y8XQV!>RG# / A 6-;Q_[+Z622<BH  R/;/0=M6C0@UAMKNTTDNR&KI1!"
M0[SGH<MF"5(IXYB=4LK,YJ4V-@EY6Z",J<5Z@:A7O.]GQ9MG'X,_SRX_GEY<
M!'_^=GI^^NE]G3E[0-MP6EWG!:C2\50*N2LI%K(>*L78*32F8%!;;P3.$!%?
MY>4&LL$'8GEX!'G"%H0\,DKX,*<D"8B MB7-RHOX%PK>99!L7TX)J?L4DP,Y
M#L/=03P\"G>/AX/#H^.C43S<WPEC$>X='T4'@_N@4"P)L=)XY%>LF+YK8L.J
MQWX!=^G@H=RE\US #X@:^,R*V>M!\+L?UMZ]*]M7B3RR$L3"5OY[8B#%-AY:
M:I36\_J.@%=6A)%<.^.'BQ_M/3/A4?>O:X98X&X=/M?X7^OYK>2HEA- ;41Z
M^+,%;+V5@M*M"3['%9%4Z=THOH)H[PIC#;5 W></IR<7I\'[D[\')\';3Y__
M.]CX=!Z<_GYR]D'^8/OSN_?XT\U &BJ7OYT&T#7NP^GEZ;O@Y..[@+K_R;]\
MQ&XD^#,'WC^X_.2+\77O^@Y$>0Z!Z($G$.W\V=F(-[",N_GK*]J-7O)= \>^
M#@Y.P%<:>+G^44&3T,](R,/F,N$$G=6??OIAF,<S_,-U-4[E'_Y_4$L#!!0
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MNDF42AVX6:@GLZ9@H-:.@7@J,Z"5JK1.? OH@@T)*3WI:?3XT(E,P9Q(?D-
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MIW%RO$G"D\%CFCX=CT8O+R\'+],#0I>CR>'A>/3GYZM[_Q&OO&$8)ZD7^WB
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MR?A; 9L00ED1N@):LFT%:ZB'6G#KB1KBN00Q36\>[EOW%0+>N ,6[*4<$'[
MM?T2X#=3IQ1[ /10J)B@'&KRK0\E(V=?^J![&K_S097.LEMMWM0#.L$-(/:%
MDPDLJ[;?]J!EMD\9_Z*KZ/:1Q/#_G3&%B\GHX0;$J6:NJ#/XFL@#Y;.L%67-
MO?C?!,:-(=6+*9.H*@6-L$,';]1C?TU9)8PG\P<^4(444[B8E!YN\BZ]8N;L
M37K8U_@>/22?98>(+-!X\M/\9R1$>WZ3WK0[I'I%92Q5Y?8=>M"A?2ROR0/U
M^+<6WK^NYB0"7H&T*(JI@8H&? )^KA U6YLH-67,K@DJ(B@/]>!%2=M>D5J+
M*],*B 6P1I_VF94Z5O@!8\6DE%@#0B4G5VQ"IB8J=>U,AG&_',*[0"H63V9/
MD@GJ@-SN+MWG&_^1;08&7HBQ291+N"QQ<!DO&[J^E />59=S+64F(DB$>O!"
MC'7#2+T%AJ_L9;5Z==>=BN]P+*W%%3OBW_Q;-(7Y-^7._@=02P,$%     @
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M4SMRYV&I5+?B@OS?\YU%?I/_J_WQ/U!+ 0(4 Q0    ( *F":532>_6 4A@
M **H   3              "  0    !B<FAC,3 P,S0Y-S)?.&LN:'1M4$L!
M A0#%     @ J8)I5!-0!AIEJ0  $< # !<              ( !@Q@  &)R
M:&,Q,# S-#DW,E]E>#$P+3$N:'1M4$L! A0#%     @ J8)I5,\$5W+D10
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M2P$"% ,4    " "I@FE4\X0H!8$(  !R6   %               @ &1Q0$
M8G1X+3(P,C(P,S V7VQA8BYX;6Q02P$"% ,4    " "I@FE4H1[[V>@%  #T
M/@  %               @ %$S@$ 8G1X+3(P,C(P,S V7W!R92YX;6Q02P4&
2      D "0!< @  7M0!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
